Art. -Nr.: HY-17422

Acyclovir

(Synonyms: Aciclovir; Acycloguanosine)

22 Cited Publications

Kundenbewertung

Based on 22 publication(s) in Google Scholar

Acyclovir (Aciclovir) is a potent, orally active antiviral agent. Acyclovir has antiherpetic activity with IC₅₀ values of 0.85 μM and 0.86 μM for HSV-1 and HSV-2, respectively. Acyclovir induces cell cycle perturbation and apoptosis. Acyclovir prevents bacterial infections during induction therapy for acute leukaemia.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.18%
CAS. Nr.: 59277-89-3
Formel: C₈H₁₁N₅O₃
Molecular Weight:225.21

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Acyclovir Chemical Structure

CAS. Nr.: 59277-89-3

Größe

Preis

Verfügbarkeit

Menge

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Massenanfrage

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (22)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[2]

HSV-1

0.85 μM (IC₅₀)

HSV-2

0.86 μM (IC₅₀)

Alle HSV Isoform-spezifische Produkte anzeigen :

Alle Antibiotic Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	CC₅₀	1555.6 μM Compound: Acyclovir	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34425312]
ARPE-19	CC₅₀	>100 μM Compound: ACV	Cytotoxicity against human ARPE-19 cells assessed as reduction in cell viability treated for 72 hrs by neutral red assay Cytotoxicity against human ARPE-19 cells assessed as reduction in cell viability treated for 72 hrs by neutral red assay	[PMID: 37140467]
BC-3	IC₅₀	>100 μM Compound: ACV	Cytotoxicity against Kaposi's sarcoma-associated herpesvirus infected BC3 cells after 120 hrs by MTT assay Cytotoxicity against Kaposi's sarcoma-associated herpesvirus infected BC3 cells after 120 hrs by MTT assay	[PMID: 17402726]
BHK-21	CC₅₀	>100 μM Compound: ACG	Cytotoxicity against hamster BHK21 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay Cytotoxicity against hamster BHK21 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay	[PMID: 19482481]
BHK-21	EC₅₀	>100 μM Compound: ACG	Antiviral activity against Reovirus-1 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay Antiviral activity against Reovirus-1 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay	[PMID: 19482481]
BHK-21	EC₅₀	>100 μM Compound: ACG	Antiviral activity against Yellow fever virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay Antiviral activity against Yellow fever virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay	[PMID: 19482481]
BHK-21	CC₅₀	>100 μM Compound: ACG	Cytotoxicity against mock-infected BHK21 cells after 48 to 96 hrs by MTT assay Cytotoxicity against mock-infected BHK21 cells after 48 to 96 hrs by MTT assay	[PMID: 25082514]
BHK-21	EC₅₀	>100 μM Compound: ACG	Antiviral activity against Reovirus type-1 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against Reovirus type-1 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 25082514]
BHK-21	EC₅₀	>100 μM Compound: ACG	Antiviral activity against Yellow fever virus infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against Yellow fever virus infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 25082514]
BHK-21	EC₅₀	>100 μM Compound: ACG	Antiviral activity against YFV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against YFV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 26443549]
BHK-21	EC₅₀	2 μM Compound: Acyclovir	Effective concentration was evaluated against HSV-1 by using serum starved baby hamster kidney cells in a colorimetric viral yield assay. Effective concentration was evaluated against HSV-1 by using serum starved baby hamster kidney cells in a colorimetric viral yield assay.	[PMID: 8863795]
BHK-21	EC₅₀	2 μM Compound: Acyclovir	Effective concentration was evaluated against HSV-2 by using serum starved baby hamster kidney cells in a colorimetric viral yield assay. Effective concentration was evaluated against HSV-2 by using serum starved baby hamster kidney cells in a colorimetric viral yield assay.	[PMID: 8863795]
BSC-1	CC₅₀	>10 μM Compound: acyclovir	Cytotoxicity against BSC1 cells Cytotoxicity against BSC1 cells	[PMID: 15615545]
BSC-1	EC₅₀	10 μM Compound: acyclovir	Inhibition of HSV1 replication in BSC1 cells by ELISA Inhibition of HSV1 replication in BSC1 cells by ELISA	[PMID: 15615545]
BSC-1	CC₅₀	>100 μM Compound: Acyclovir	Cytotoxic concentration required to inhibit herpes simplex virus 1 infected BSC-1 cells Cytotoxic concentration required to inhibit herpes simplex virus 1 infected BSC-1 cells	[PMID: 15634003]
BSC-1	EC₅₀	1.5 μM Compound: Acyclovir	Effective concentration required to inhibit herpes simplex virus 1 in BSC-1 cells in ELISA Effective concentration required to inhibit herpes simplex virus 1 in BSC-1 cells in ELISA	[PMID: 15634003]
BSC-1	EC₅₀	3.5 μM Compound: acyclovir	Inhibition of HSV1 replication in BSC1 cells by ELISA Inhibition of HSV1 replication in BSC1 cells by ELISA	[PMID: 17004726]
BSC-1	EC₅₀	0.3 μM Compound: Acyclovir	Antiviral activity against Herpes simplex virus type 1 in african green monkey BSC1 cells by plaque reduction assay Antiviral activity against Herpes simplex virus type 1 in african green monkey BSC1 cells by plaque reduction assay	[PMID: 19410465]
BSC-1	IC₅₀	>100 μM Compound: Acyclovir	Tested in vitro for cytotoxicity against the monkey kidney cells (BSC-1 cells). Tested in vitro for cytotoxicity against the monkey kidney cells (BSC-1 cells).	[PMID: 2175356]
BSC-1	IC₅₀	>100 μM Compound: Acyclovir	Cytotoxicity against Monkey kidney cells(BSC-1 cells) Cytotoxicity against Monkey kidney cells(BSC-1 cells)	[PMID: 2500527]
BSC-1	IC₅₀	>100 μM Compound: 1 (acyclovir)	The compound was tested for cytotoxicity against BSC1 cell The compound was tested for cytotoxicity against BSC1 cell	[PMID: 2840500]
BSC-1	IC₅₀	2.6 μM Compound: Acyclovir	Antiviral activity of the compound was evaluated against the Herpes simplex virus type-1 in BSC-1 cells Antiviral activity of the compound was evaluated against the Herpes simplex virus type-1 in BSC-1 cells	[PMID: 2913300]
CCRF-CEM	IC₅₀	>440 μM Compound: Acyclovir	In vitro anti-HIV screen using HIV-1 infected CD4 lymphocytes (CEM cell line), determines cytotoxicity In vitro anti-HIV screen using HIV-1 infected CD4 lymphocytes (CEM cell line), determines cytotoxicity	[PMID: 11814776]
CCRF-CEM	CC₅₀	>200 μM Compound: Acyclovir	Compound concentration required to reduce viability of CEM cells Compound concentration required to reduce viability of CEM cells	[PMID: 14643328]
CCRF-CEM	EC₅₀	>200 μM Compound: Acyclovir	Compound was tested for anti-viral activity against HIV-1 in CEM cells Compound was tested for anti-viral activity against HIV-1 in CEM cells	[PMID: 14643328]
CCRF-CEM	EC₅₀	>200 μM Compound: Acyclovir	Compound was tested for anti-viral activity against HIV-2 in CEM cells Compound was tested for anti-viral activity against HIV-2 in CEM cells	[PMID: 14643328]
CCRF-CEM	EC₅₀	>50 μM Compound: Acyclovir	Antiviral activity against HIV1 IIIB in CEM cells Antiviral activity against HIV1 IIIB in CEM cells	[PMID: 16392791]
CCRF-CEM	EC₅₀	>50 μM Compound: Acyclovir	Antiviral activity against HIV2 ROD in CEM cells Antiviral activity against HIV2 ROD in CEM cells	[PMID: 16392791]
CCRF-CEM	EC₅₀	>250 μM Compound: 1, ACV	Antiviral activity against HIV1 3B/Lai infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days Antiviral activity against HIV1 3B/Lai infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days	[PMID: 19645484]
CCRF-CEM	EC₅₀	>250 μM Compound: 1, ACV	Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days	[PMID: 19645484]
CCRF-CEM	IC₅₀	>250 μM Compound: 1, ACV	Cytotoxicity against human CEM cells assessed as decrease in cell viability Cytotoxicity against human CEM cells assessed as decrease in cell viability	[PMID: 19645484]
CCRF-HSB-2	IC₅₀	>100 μg/mL Compound: acyclovir	Antiproliferative effects on CCRF-HSB-2 (human leukemia) cells. Antiproliferative effects on CCRF-HSB-2 (human leukemia) cells.	[PMID: 9216836]
Daudi	CC₅₀	>222 μM Compound: acyclovir	Cytotoxicity against Daudi cells Cytotoxicity against Daudi cells	[PMID: 15615545]
Daudi	EC₅₀	1.1 μM Compound: acyclovir	Inhibition of EBV replication in Daudi cells by VCA ELISA Inhibition of EBV replication in Daudi cells by VCA ELISA	[PMID: 15615545]
Daudi	EC₅₀	5.3 μM Compound: acyclovir	Inhibition of EBV replication in Daudi cells by DNA hybridization assay Inhibition of EBV replication in Daudi cells by DNA hybridization assay	[PMID: 15615545]
Daudi	CC₅₀	>222 μM Compound: Acyclovir	Cytotoxic concentration to inhibit replication in daudi cells Cytotoxic concentration to inhibit replication in daudi cells	[PMID: 15634003]
Daudi	CC₅₀	>100 μM Compound: acyclovir	Cytotoxicity against Daudi cells Cytotoxicity against Daudi cells	[PMID: 17004726]
Daudi	EC₅₀	0.33 μM Compound: acyclovir	Inhibition of EBV replication in Daudi cells by viral capsid antigen-ELISA Inhibition of EBV replication in Daudi cells by viral capsid antigen-ELISA	[PMID: 17004726]
DG-75	IC₅₀	>100 μM Compound: ACV	Cytotoxicity against DG75 cells after 120 hrs by MTT assay Cytotoxicity against DG75 cells after 120 hrs by MTT assay	[PMID: 17402726]
E6SM	EC₅₀	>400 μg/mL Compound: Acyclovir	Inhibitory activity against vaccinia virus (VV) replication in E6SM cell cultures of human embryonic skin-muscle Inhibitory activity against vaccinia virus (VV) replication in E6SM cell cultures of human embryonic skin-muscle	[PMID: 12459010]
E6SM	EC₅₀	>400 μg/mL Compound: Acyclovir	Inhibitory activity against vesicular stomatitis virus (VSV) replication in E6SM cell cultures of human embryonic skin-muscle Inhibitory activity against vesicular stomatitis virus (VSV) replication in E6SM cell cultures of human embryonic skin-muscle	[PMID: 12459010]
E6SM	EC₅₀	0.077 μg/mL Compound: Acyclovir	Inhibitory activity against HSV-1 (F) replication in E6SM cell cultures of human embryonic skin-muscle Inhibitory activity against HSV-1 (F) replication in E6SM cell cultures of human embryonic skin-muscle	[PMID: 12459010]
E6SM	EC₅₀	0.077 μg/mL Compound: Acyclovir	Inhibitory activity against HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle Inhibitory activity against HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle	[PMID: 12459010]
E6SM	EC₅₀	0.077 μg/mL Compound: Acyclovir	Inhibitory activity against HSV-1 (McIntyre) replication in E6SM cell cultures of human embryonic skin-muscle Inhibitory activity against HSV-1 (McIntyre) replication in E6SM cell cultures of human embryonic skin-muscle	[PMID: 12459010]
E6SM	EC₅₀	0.384 μg/mL Compound: Acyclovir	Inhibitory activity against HSV-2 (196) replication in E6SM cell cultures of human embryonic skin-muscle Inhibitory activity against HSV-2 (196) replication in E6SM cell cultures of human embryonic skin-muscle	[PMID: 12459010]
E6SM	EC₅₀	0.384 μg/mL Compound: Acyclovir	Inhibitory activity against HSV-2 (G) replication in E6SM cell cultures of human embryonic skin-muscle Inhibitory activity against HSV-2 (G) replication in E6SM cell cultures of human embryonic skin-muscle	[PMID: 12459010]
E6SM	EC₅₀	0.384 μg/mL Compound: Acyclovir	Inhibitory activity against HSV-2 (Lyons) replication in E6SM cell cultures of human embryonic skin-muscle Inhibitory activity against HSV-2 (Lyons) replication in E6SM cell cultures of human embryonic skin-muscle	[PMID: 12459010]
E6SM	EC₅₀	48 μg/mL Compound: Acyclovir	Inhibitory activity against TK-deficient HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle Inhibitory activity against TK-deficient HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle	[PMID: 12459010]
E6SM	EC₅₀	0.07 μg/mL Compound: acyclovir	Effective concentration required to reduce HSV-1 strain KOS virus plaque formation by 50% in E6SM Cell Culture Effective concentration required to reduce HSV-1 strain KOS virus plaque formation by 50% in E6SM Cell Culture	[PMID: 15481985]
E6SM	EC₅₀	0.07 μg/mL Compound: acyclovir	Effective concentration required to reduce HSV-2 strain G virus plaque formation by 50% in E6SM Cell Culture Effective concentration required to reduce HSV-2 strain G virus plaque formation by 50% in E6SM Cell Culture	[PMID: 15481985]
E6SM	EC₅₀	0.38 μg/mL Compound: acyclovir	Effective concentration required to reduce vaccinia virus plaque formation by 50% in E6SM Cell Culture Effective concentration required to reduce vaccinia virus plaque formation by 50% in E6SM Cell Culture	[PMID: 15481985]
E6SM	EC₅₀	48 μg/mL Compound: acyclovir	Effective concentration required to reduce HSV-1 strain KOS ACV virus plaque formation by 50% in E6SM Cell Culture Effective concentration required to reduce HSV-1 strain KOS ACV virus plaque formation by 50% in E6SM Cell Culture	[PMID: 15481985]
E6SM	EC₅₀	>400 μg/mL Compound: acyclovir	Antiviral activity against Vaccinia virus in E6SM cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Vaccinia virus in E6SM cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17518459]
E6SM	EC₅₀	0.02 μg/mL Compound: acyclovir	Antiviral activity against HSV1 KOS in E6SM cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HSV1 KOS in E6SM cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17518459]
E6SM	EC₅₀	0.07 μg/mL Compound: acyclovir	Antiviral activity against HSV2 G in E6SM cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HSV2 G in E6SM cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17518459]
E6SM	EC₅₀	40 μg/mL Compound: acyclovir	Antiviral activity against thymidine kinase-deficient HSV1 B2006 in E6SM cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against thymidine kinase-deficient HSV1 B2006 in E6SM cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17518459]
E6SM	EC₅₀	7 μg/mL Compound: acyclovir	Antiviral activity against thymidine kinase deficient HSV1 VMW1837 in E6SM cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against thymidine kinase deficient HSV1 VMW1837 in E6SM cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17518459]
E6SM	CC₅₀	>400 μg/mL Compound: acyclovir	Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of E6SM cells Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of E6SM cells	[PMID: 8709116]
E6SM	IC₅₀	0.015 μg/mL Compound: Acyclovir	Antiviral activity against herpes simplex virus-1 KOS in E6SM cell culture Antiviral activity against herpes simplex virus-1 KOS in E6SM cell culture	[PMID: 8831773]
E6SM	IC₅₀	0.02 μg/mL Compound: Acyclovir	Antiviral activity in herpes simplex virus-2 (HSV-2) G strain in E6SM cell culture Antiviral activity in herpes simplex virus-2 (HSV-2) G strain in E6SM cell culture	[PMID: 8831773]
Fibroblast	IC₅₀	>100 μM Compound: Acyclovir	Cytotoxicity against Normal human diploid cells (human foreskin fibroblasts cells) Cytotoxicity against Normal human diploid cells (human foreskin fibroblasts cells)	[PMID: 2500527]
Fibroblast	IC₅₀	>440 μM Compound: acyclovir	Concentration of the drug required to reduce the proliferation of human foreskin fibroblast cells Concentration of the drug required to reduce the proliferation of human foreskin fibroblast cells	[PMID: 8394933]
HEL	CC₅₀	>200 μg/mL Compound: Acyclovir	The concentration required to reduce cell growth by 50% was measured on Human Embryonic Lung (HEL) cells The concentration required to reduce cell growth by 50% was measured on Human Embryonic Lung (HEL) cells	[PMID: 10197958]
HEL	IC₅₀	>100 μM Compound: ACV	The compound was tested for cytotoxic concentration required to reduce human embryonic lung cell growth by 50% The compound was tested for cytotoxic concentration required to reduce human embryonic lung cell growth by 50%	[PMID: 10411487]
HEL	IC₅₀	>50 μM Compound: ACV	Minimum cytotoxic concentration that causes a microscopically detectable alteration of cell morphology in human embryonic lung cells Minimum cytotoxic concentration that causes a microscopically detectable alteration of cell morphology in human embryonic lung cells	[PMID: 10411487]
HEL	IC₅₀	0.16 μM Compound: ACV	The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK+OKA strain The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK+OKA strain	[PMID: 10411487]
HEL	IC₅₀	0.78 μM Compound: ACV	The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK+YS strain The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK+YS strain	[PMID: 10411487]
HEL	IC₅₀	12 μM Compound: ACV	The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK-(deficient) YS/R strain The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK-(deficient) YS/R strain	[PMID: 10411487]
HEL	IC₅₀	17 μM Compound: ACV	The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK-(deficient) 07/1 strain The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK-(deficient) 07/1 strain	[PMID: 10411487]
HEL	IC₅₀	>200 μM Compound: 5 (ACV)	Compound was evaluated for the anti-viral activity against HEL cells Compound was evaluated for the anti-viral activity against HEL cells	[PMID: 10579812]
HEL	IC₅₀	3.4 μg/mL Compound: ACV	Tested for inhibitory activity against Varicella zoster virus(VZV) by plaque reduction assay using HEL cells Tested for inhibitory activity against Varicella zoster virus(VZV) by plaque reduction assay using HEL cells	[PMID: 10649983]
HEL	IC₅₀	3.4 μg/mL Compound: ACV	Tested for Antiherpetic activity against VZV from Kawaguchi strain in HEL cell lines. Tested for Antiherpetic activity against VZV from Kawaguchi strain in HEL cell lines.	[PMID: 10649983]
HEL	IC₅₀	5.4 μg/mL Compound: ACV	Tested for Antiherpetic activity against VZV from clinical isolates of HEL cell lines.(average of 11 isolates) Tested for Antiherpetic activity against VZV from clinical isolates of HEL cell lines.(average of 11 isolates)	[PMID: 10649983]
HEL	CC₅₀	>200 μM Compound: ACV acyclovir	The compound was tested for cytotoxic concentration required to inhibit Hel cell growth by 50% The compound was tested for cytotoxic concentration required to inhibit Hel cell growth by 50%	[PMID: 10866384]
HEL	CC₅₀	>400 μM Compound: acyclovir	Inhibition of cell growth in HEL cells. Inhibition of cell growth in HEL cells.	[PMID: 10966745]
HEL	CC₅₀	>200 μM Compound: 5 (Acyclovir)	cytostatic concentration required to reduce the HEL cell number by 50%. after 5 days in the absence of virus cytostatic concentration required to reduce the HEL cell number by 50%. after 5 days in the absence of virus	[PMID: 11150169]
HEL	EC₅₀	1 μM Compound: 5 (Acyclovir)	Evaluated for the anti-VZV activity, the concentration of compounds in uM required to reduce VZV TS plaque formation after 5 days in HEL cell cultures compared to untreated controls. Evaluated for the anti-VZV activity, the concentration of compounds in uM required to reduce VZV TS plaque formation after 5 days in HEL cell cultures compared to untreated controls.	[PMID: 11150169]
HEL	EC₅₀	125 μM Compound: 5 (Acyclovir)	Evaluated for the anti-VZV, the concentration of compounds in uM required to reduce VZVTK-YS-R ( thymidine kinase-deficient strain ) plaque formation after 5 days in HEL cell cultures compared to untreated controls. Evaluated for the anti-VZV, the concentration of compounds in uM required to reduce VZVTK-YS-R ( thymidine kinase-deficient strain ) plaque formation after 5 days in HEL cell cultures compared to untreated controls.	[PMID: 11150169]
HEL	EC₅₀	2.9 μM Compound: 5 (Acyclovir)	Evaluated for the anti-VZV activity, the concentration of compounds in uM required to reduce VZV OKA Plaque formation after 5 days in HEL cell cultures compared to untreated controls. Evaluated for the anti-VZV activity, the concentration of compounds in uM required to reduce VZV OKA Plaque formation after 5 days in HEL cell cultures compared to untreated controls.	[PMID: 11150169]
HEL	EC₅₀	74 μM Compound: 5 (Acyclovir)	Evaluated for the anti-VZV, the concentration of compounds in uM required to reduce VZVTK-07 ( thymidine kinase-deficient strain ) plaque formation after 5 days in HEL cell cultures compared to untreated controls. Evaluated for the anti-VZV, the concentration of compounds in uM required to reduce VZVTK-07 ( thymidine kinase-deficient strain ) plaque formation after 5 days in HEL cell cultures compared to untreated controls.	[PMID: 11150169]
HEL	CC₅₀	>200 μM Compound: 4	Cytotoxic concentration required to inhibit HEL cell growth by 50 % Cytotoxic concentration required to inhibit HEL cell growth by 50 %	[PMID: 11212118]
HEL	EC₅₀	4.09 μM Compound: Acyclovir, ACV	Effective concentration required to inhibit Tyrosine kinase (TK+) Varicella-Zoster virus-induced cytopathicity by 50% in YS strain HEL cell lines Effective concentration required to inhibit Tyrosine kinase (TK+) Varicella-Zoster virus-induced cytopathicity by 50% in YS strain HEL cell lines	[PMID: 11495586]
HEL	EC₅₀	4.53 μM Compound: Acyclovir, ACV	Effective concentration required to inhibit Tyrosine kinase (TK+) Varicella-Zoster virus-induced cytopathicity by 50% in OKA strain HEL cell lines Effective concentration required to inhibit Tyrosine kinase (TK+) Varicella-Zoster virus-induced cytopathicity by 50% in OKA strain HEL cell lines	[PMID: 11495586]
HEL	EC₅₀	41 μM Compound: Acyclovir, ACV	Effective concentration required to inhibit Tyrosine kinase deficient (TK-) Varicella-Zoster virus-induced cytopathicity by 50% in 07/01 strain HEL cell lines Effective concentration required to inhibit Tyrosine kinase deficient (TK-) Varicella-Zoster virus-induced cytopathicity by 50% in 07/01 strain HEL cell lines	[PMID: 11495586]
HEL	EC₅₀	63 μM Compound: Acyclovir, ACV	Effective concentration required to inhibit Tyrosine kinase deficient (TK-) Varicella-Zoster virus-induced cytopathicity by 50% in YS/R strain HEL cell lines Effective concentration required to inhibit Tyrosine kinase deficient (TK-) Varicella-Zoster virus-induced cytopathicity by 50% in YS/R strain HEL cell lines	[PMID: 11495586]
HEL	CC₅₀	>400 μM Compound: (ACV)acyclovir	Cytotoxic concentration required to inhibit growth of human embryonic lung cells (HEL) Cytotoxic concentration required to inhibit growth of human embryonic lung cells (HEL)	[PMID: 11549457]
HEL	EC₅₀	1.1 μM Compound: (ACV)acyclovir	Antiviral activity was measured as effective concentration required to reduce Varicella Zoster virus (OKA)-induced plaque formation in human embryonic lung cells Antiviral activity was measured as effective concentration required to reduce Varicella Zoster virus (OKA)-induced plaque formation in human embryonic lung cells	[PMID: 11549457]
HEL	EC₅₀	1.5 μM Compound: (ACV)acyclovir	Antiviral activity was measured as effective concentration required to reduce Varicella Zoster virus (YS)-induced plaque formation in human embryonic lung cells Antiviral activity was measured as effective concentration required to reduce Varicella Zoster virus (YS)-induced plaque formation in human embryonic lung cells	[PMID: 11549457]
HEL	EC₅₀	40 μM Compound: (ACV)acyclovir	Antiviral activity was measured as effective concentration required to reduce thymidine kinase-deficient. Varicella Zoster virus (07/1)-induced plaque formation in human embryonic lung cells Antiviral activity was measured as effective concentration required to reduce thymidine kinase-deficient. Varicella Zoster virus (07/1)-induced plaque formation in human embryonic lung cells	[PMID: 11549457]
HEL	EC₅₀	44 μM Compound: (ACV)acyclovir	Antiviral activity was measured as effective concentration required to reduce thymidine kinase-deficient. Varicella Zoster virus (YS/R)-induced plaque formation in human embryonic lung cells Antiviral activity was measured as effective concentration required to reduce thymidine kinase-deficient. Varicella Zoster virus (YS/R)-induced plaque formation in human embryonic lung cells	[PMID: 11549457]
HEL	CC₅₀	>200 μg/mL Compound: Acyclovir	Cytotoxic concentration reducing HEL cell growth by 50%. Cytotoxic concentration reducing HEL cell growth by 50%.	[PMID: 12217359]
HEL	CC₅₀	>1700 μM Compound: Acyclovir	Compound concentration required to reduce viability of HEL cells Compound concentration required to reduce viability of HEL cells	[PMID: 14643328]
HEL	EC₅₀	0.32 μM Compound: Acyclovir	Compound was tested for anti-viral activity against HSV-1(KOS) in HEL cells Compound was tested for anti-viral activity against HSV-1(KOS) in HEL cells	[PMID: 14643328]
HEL	EC₅₀	1.3 μM Compound: Acyclovir	Compound was tested for anti-viral activity against HSV-1(G) in HEL cells Compound was tested for anti-viral activity against HSV-1(G) in HEL cells	[PMID: 14643328]
HEL	EC₅₀	88 μM Compound: Acyclovir	Compound was tested for anti-viral activity against HSV-1TK neg in HEL cells Compound was tested for anti-viral activity against HSV-1TK neg in HEL cells	[PMID: 14643328]
HEL	EC₅₀	>200 μM Compound: acyclovir	Effective concentration required to reduce CMV AD169 strain virus plaque formation by 50% in HEL cell culture Effective concentration required to reduce CMV AD169 strain virus plaque formation by 50% in HEL cell culture	[PMID: 15481985]
HEL	EC₅₀	>400 μM Compound: acyclovir	Effective concentration required to reduce CMV davis strain virus plaque formation by 50% in HEL cell culture Effective concentration required to reduce CMV davis strain virus plaque formation by 50% in HEL cell culture	[PMID: 15481985]
HEL	EC₅₀	0.9 μM Compound: acyclovir	Effective concentration required to reduce TK+ (thymidine kinase presence) VZV strain OKA virus plaque formation by 50% in HEL cell culture Effective concentration required to reduce TK+ (thymidine kinase presence) VZV strain OKA virus plaque formation by 50% in HEL cell culture	[PMID: 15481985]
HEL	EC₅₀	1.3 μM Compound: acyclovir	Effective concentration required to reduce TK+ (thymidine kinase presence) VZV strain YS virus plaque formation by 50% in HEL cell culture Effective concentration required to reduce TK+ (thymidine kinase presence) VZV strain YS virus plaque formation by 50% in HEL cell culture	[PMID: 15481985]
HEL	EC₅₀	24 μM Compound: acyclovir	Effective concentration required to reduce TK+ (thymidine kinase deficient) VZV strain 07/1 virus plaque formation by 50% in HEL cell culture Effective concentration required to reduce TK+ (thymidine kinase deficient) VZV strain 07/1 virus plaque formation by 50% in HEL cell culture	[PMID: 15481985]
HEL	EC₅₀	27 μM Compound: acyclovir	Effective concentration required to reduce TK+ (thymidine kinase deficient) VZV strain YS/R virus plaque formation by 50% in HEL cell culture Effective concentration required to reduce TK+ (thymidine kinase deficient) VZV strain YS/R virus plaque formation by 50% in HEL cell culture	[PMID: 15481985]
HEL	EC₅₀	0.32 μM Compound: Acyclovir	Effective concentration required to inhibit herpes simplex virus type 1 Kos strain induced cytopathicity in Hel cells Effective concentration required to inhibit herpes simplex virus type 1 Kos strain induced cytopathicity in Hel cells	[PMID: 15658858]
HEL	CC₅₀	200 μg/mL Compound: ACV (Acyclovir)	Cytotoxic concentration to reduce the 50% cell growth of human embryonic lung cells Cytotoxic concentration to reduce the 50% cell growth of human embryonic lung cells	[PMID: 15658861]
HEL	CC₅₀	511 μM Compound: Acyclovir	Cytotoxic concentration required to reduce HEL cell growth Cytotoxic concentration required to reduce HEL cell growth	[PMID: 15801851]
HEL	EC₅₀	111 μM Compound: Acyclovir	Effective concentration required to reduce Varicella-Zoster virus 07/1(TK-) plaque formation after 5 days in HEL fibroblast cell line Effective concentration required to reduce Varicella-Zoster virus 07/1(TK-) plaque formation after 5 days in HEL fibroblast cell line	[PMID: 15801851]
HEL	EC₅₀	17 μM Compound: Acyclovir	Effective concentration required to inhibit human cytomegalo virus AD-169 induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection Effective concentration required to inhibit human cytomegalo virus AD-169 induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection	[PMID: 15801851]
HEL	EC₅₀	20 μM Compound: Acyclovir	Effective concentration required to inhibit human cytomegalo virus Davis induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection Effective concentration required to inhibit human cytomegalo virus Davis induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection	[PMID: 15801851]
HEL	EC₅₀	7.1 μM Compound: Acyclovir	Effective concentration required to reduce Varicella-Zoster virus OKA(TK) plaque formation after 5 days in HEL fibroblast cell line Effective concentration required to reduce Varicella-Zoster virus OKA(TK) plaque formation after 5 days in HEL fibroblast cell line	[PMID: 15801851]
HEL	EC₅₀	1.12 μM Compound: Acyclovir	Antiviral activity against HSV1 KOS in HEL cells Antiviral activity against HSV1 KOS in HEL cells	[PMID: 16392791]
HEL	EC₅₀	1.76 μM Compound: Acyclovir	Antiviral activity against HSV2 G in HEL cells Antiviral activity against HSV2 G in HEL cells	[PMID: 16392791]
HEL	EC₅₀	86.6 μM Compound: Acyclovir	Antiviral activity against HSV1 TK- in HEL cells Antiviral activity against HSV1 TK- in HEL cells	[PMID: 16392791]
HEL	CC₅₀	>889 μM Compound: ACV	Cytotoxic activity against cultured human embryonic lung (HEL) cells Cytotoxic activity against cultured human embryonic lung (HEL) cells	[PMID: 16392824]
HEL	CC₅₀	118 μg/mL Compound: acyclovir	Cytotoxicity against HEL cells Cytotoxicity against HEL cells	[PMID: 16480257]
HEL	CC₅₀	>500 μM Compound: Acyclovir	Cytotoxicity against HEL cells Cytotoxicity against HEL cells	[PMID: 17181162]
HEL	EC₅₀	>500 μM Compound: Acyclovir	Antiviral activity against vesicular somatitis virus in HEL cells Antiviral activity against vesicular somatitis virus in HEL cells	[PMID: 17181162]
HEL	EC₅₀	0.48 μM Compound: Acyclovir	Antiviral activity against HSV2 in HEL cells Antiviral activity against HSV2 in HEL cells	[PMID: 17181162]
HEL	EC₅₀	300 μM Compound: Acyclovir	Antiviral activity against vaccinia virus in HEL cells Antiviral activity against vaccinia virus in HEL cells	[PMID: 17181162]
HEL	EC₅₀	>20 μg/mL Compound: acyclovir	Antiviral activity against ACV-resistant TK- HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against ACV-resistant TK- HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
HEL	EC₅₀	>=25.1 μg/mL Compound: acyclovir	Antiviral activity against TK- VZV 07-1 in HEL cells assessed as inhibition of plaque formation Antiviral activity against TK- VZV 07-1 in HEL cells assessed as inhibition of plaque formation	[PMID: 17298047]
HEL	EC₅₀	0.015 μg/mL Compound: acyclovir	Antiviral activity against HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
HEL	EC₅₀	0.018 μg/mL Compound: acyclovir	Antiviral activity against HSV2 Lyons in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against HSV2 Lyons in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
HEL	EC₅₀	0.048 μg/mL Compound: acyclovir	Antiviral activity against HSV2 G in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against HSV2 G in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
HEL	EC₅₀	0.75 μg/mL Compound: acyclovir	Antiviral activity against VZV OKA in HEL cells assessed as inhibition of plaque formation Antiviral activity against VZV OKA in HEL cells assessed as inhibition of plaque formation	[PMID: 17298047]
HEL	CC₅₀	649 μM Compound: acyclovir	Cytotoxicity against HEL cells assessed as cell growth after 7 days Cytotoxicity against HEL cells assessed as cell growth after 7 days	[PMID: 17539622]
HEL	CC₅₀	200 μg/mL Compound: Acyclovir	Cytotoxicity against human HEL cells assessed as reduction of cell growth Cytotoxicity against human HEL cells assessed as reduction of cell growth	[PMID: 17583388]
HEL	EC₅₀	0.17 μg/mL Compound: Acyclovir	Antiviral activity against TK+ VZV OKA infected HEL cells assessed as reduction in virus plaque formation Antiviral activity against TK+ VZV OKA infected HEL cells assessed as reduction in virus plaque formation	[PMID: 17583388]
HEL	EC₅₀	16 μg/mL Compound: Acyclovir	Antiviral activity against TK- VZV 07/1 infected HEL cells assessed as reduction in virus plaque formation Antiviral activity against TK- VZV 07/1 infected HEL cells assessed as reduction in virus plaque formation	[PMID: 17583388]
HEL	CC₅₀	>890 μM Compound: ACV	Cytotoxicity against HEL cells after 3 days Cytotoxicity against HEL cells after 3 days	[PMID: 17622128]
HEL	EC₅₀	1.4 μM Compound: ACV	Antiviral activity against TK+ VZV YS in HEL cells assessed as reduction of virus plaque formation after 5 days Antiviral activity against TK+ VZV YS in HEL cells assessed as reduction of virus plaque formation after 5 days	[PMID: 17622128]
HEL	EC₅₀	24 μM Compound: ACV	Antiviral activity against thymidine kinase deficient VZV YS/R in HEL cells assessed as reduction of virus plaque formation after 5 days Antiviral activity against thymidine kinase deficient VZV YS/R in HEL cells assessed as reduction of virus plaque formation after 5 days	[PMID: 17622128]
HEL	EC₅₀	36 μM Compound: ACV	Antiviral activity against thymidine kinase deficient VZV 07/1 in HEL cells assessed as reduction of virus plaque formation after 5 days Antiviral activity against thymidine kinase deficient VZV 07/1 in HEL cells assessed as reduction of virus plaque formation after 5 days	[PMID: 17622128]
HEL	EC₅₀	4 μM Compound: ACV	Antiviral activity against TK+ VZV OKA in HEL cells assessed as reduction of virus plaque formation after 5 days Antiviral activity against TK+ VZV OKA in HEL cells assessed as reduction of virus plaque formation after 5 days	[PMID: 17622128]
HEL	CC₅₀	545 μM Compound: acyclovir	Cytotoxicity against human HEL cells assessed as reduction of cell growth Cytotoxicity against human HEL cells assessed as reduction of cell growth	[PMID: 17672445]
HEL	EC₅₀	1 μM Compound: acyclovir	Antiviral activity against thymidine kinase-positive VZV OKA in human HEL cells after 7 days Antiviral activity against thymidine kinase-positive VZV OKA in human HEL cells after 7 days	[PMID: 17672445]
HEL	EC₅₀	32 μM Compound: acyclovir	Antiviral activity against thymidine kinase deficient VZV 07/1 in human HEL cells after 7 days Antiviral activity against thymidine kinase deficient VZV 07/1 in human HEL cells after 7 days	[PMID: 17672445]
HEL	CC₅₀	>200 μg/mL Compound: acyclovir	Cytotoxicity against HEL cells assessed as reduction of cell growth after 3 days Cytotoxicity against HEL cells assessed as reduction of cell growth after 3 days	[PMID: 17869124]
HEL	EC₅₀	0.7 μg/mL Compound: acyclovir	Antiviral activity against TK+ VZV OKA in HEL cells assessed as reduction of virus plaque formation Antiviral activity against TK+ VZV OKA in HEL cells assessed as reduction of virus plaque formation	[PMID: 17869124]
HEL	EC₅₀	28 μg/mL Compound: acyclovir	Antiviral activity against TK- VZV 07/1 in HEL cells assessed as reduction of virus plaque formation Antiviral activity against TK- VZV 07/1 in HEL cells assessed as reduction of virus plaque formation	[PMID: 17869124]
HEL	CC₅₀	212 μg/mL Compound: acyclovir	Cytotoxicity against HEL cells assessed as cell growth after 3 days Cytotoxicity against HEL cells assessed as cell growth after 3 days	[PMID: 17948980]
HEL	EC₅₀	>=25.2 μg/mL Compound: acyclovir	Antiviral activity against acyclovir-resistant HSV1 KOS TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against acyclovir-resistant HSV1 KOS TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	0.02 μg/mL Compound: acyclovir	Antiviral activity against HSV2 Lyons in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HSV2 Lyons in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	0.03 μg/mL Compound: acyclovir	Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	0.05 μg/mL Compound: acyclovir	Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	0.23 μg/mL Compound: acyclovir	Antiviral activity against VZV OKA in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against VZV OKA in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	10.2 μg/mL Compound: acyclovir	Antiviral activity against VZV 07-1 TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against VZV 07-1 TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	CC₅₀	>200 μM Compound: 14, acyclovir	Cytotoxicity against HEL cells Cytotoxicity against HEL cells	[PMID: 18052321]
HEL	EC₅₀	1 μM Compound: 14, acyclovir	Antiviral activity against TK+ VZV YS in HEL cells after 5 days Antiviral activity against TK+ VZV YS in HEL cells after 5 days	[PMID: 18052321]
HEL	EC₅₀	125 μM Compound: 14, acyclovir	Antiviral activity against TK- VZV YS in HEL cells after 5 days Antiviral activity against TK- VZV YS in HEL cells after 5 days	[PMID: 18052321]
HEL	EC₅₀	2.9 μM Compound: 14, acyclovir	Antiviral activity against TK+ VZV OKA in HEL cells after 5 days Antiviral activity against TK+ VZV OKA in HEL cells after 5 days	[PMID: 18052321]
HEL	EC₅₀	74 μM Compound: 14, acyclovir	Antiviral activity against TK- VZV 07 in HEL cells after 5 days Antiviral activity against TK- VZV 07 in HEL cells after 5 days	[PMID: 18052321]
HEL	CC₅₀	1350 μM Compound: 1, ACV	Cytotoxicity against HEL cells assessed as inhibition of cell proliferation Cytotoxicity against HEL cells assessed as inhibition of cell proliferation	[PMID: 18614365]
HEL	EC₅₀	0.2 μM Compound: 1, ACV	Antiviral activity against HSV2 G in HEL cells assessed as inhibition of virus induced cytopathicity within 48 hrs Antiviral activity against HSV2 G in HEL cells assessed as inhibition of virus induced cytopathicity within 48 hrs	[PMID: 18614365]
HEL	EC₅₀	0.4 μM Compound: 1, ACV	Antiviral activity against HSV1 KOS in HEL cells assessed as inhibition of virus induced cytopathicity within 48 hrs Antiviral activity against HSV1 KOS in HEL cells assessed as inhibition of virus induced cytopathicity within 48 hrs	[PMID: 18614365]
HEL	EC₅₀	2.5 μM Compound: 1, ACV	Antiviral activity against TK+ VZV OKA infected HEL cells assessed as reduction in virus plaque formation after 5 days Antiviral activity against TK+ VZV OKA infected HEL cells assessed as reduction in virus plaque formation after 5 days	[PMID: 18614365]
HEL	EC₅₀	2.9 μM Compound: 1, ACV	Antiviral activity against TK+ VZV YS infected HEL cells assessed as reduction in virus plaque formation after 5 days Antiviral activity against TK+ VZV YS infected HEL cells assessed as reduction in virus plaque formation after 5 days	[PMID: 18614365]
HEL	EC₅₀	43 μM Compound: 1, ACV	Antiviral activity against thymidine kinase deficient VZV YS/R infected HEL cells assessed as reduction in virus plaque formation after 5 days Antiviral activity against thymidine kinase deficient VZV YS/R infected HEL cells assessed as reduction in virus plaque formation after 5 days	[PMID: 18614365]
HEL	EC₅₀	50 μM Compound: 1, ACV	Antiviral activity against acyclovir-resistant and thymidine kinase deficient HSV1 KOS in HEL cells assessed as inhibition of virus induced cytopathicity within 48 hrs Antiviral activity against acyclovir-resistant and thymidine kinase deficient HSV1 KOS in HEL cells assessed as inhibition of virus induced cytopathicity within 48 hrs	[PMID: 18614365]
HEL	EC₅₀	61 μM Compound: 1, ACV	Antiviral activity against thymidine kinase deficient VZV 07/1 infected HEL cells assessed as reduction in virus plaque formation after 5 days Antiviral activity against thymidine kinase deficient VZV 07/1 infected HEL cells assessed as reduction in virus plaque formation after 5 days	[PMID: 18614365]
HEL	EC₅₀	12 μg/mL Compound: ACV	Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl cytosine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl cytosine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	130 μg/mL Compound: ACV	Antiviral activity against acyclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against acyclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	173 μg/mL Compound: ACV	Antiviral activity against foscarnet-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against foscarnet-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	22 μg/mL Compound: ACV	Antiviral activity against HCMV 530 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HCMV 530 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	4.8 μg/mL Compound: ACV	Antiviral activity against ganciclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against ganciclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	7.7 μg/mL Compound: ACV	Antiviral activity against HCMV 521 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HCMV 521 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	7.9 μg/mL Compound: ACV	Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl adenine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl adenine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	EC₅₀	91 μg/mL Compound: ACV	Antiviral activity against HCMV 6 with U97 mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HCMV 6 with U97 mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 18707089]
HEL	CC₅₀	137 μg/mL Compound: aciclovir	Cytotoxicity against HEL cells assessed as reduction of growth after 3 days Cytotoxicity against HEL cells assessed as reduction of growth after 3 days	[PMID: 18835175]
HEL	EC₅₀	0.24 μg/mL Compound: aciclovir	Antiviral activity against thymidine kinase expressing Varicella-Zoster virus Oka in HEL cells assessed as inhibition of viral cytopathicity Antiviral activity against thymidine kinase expressing Varicella-Zoster virus Oka in HEL cells assessed as inhibition of viral cytopathicity	[PMID: 18835175]
HEL	EC₅₀	13 μg/mL Compound: aciclovir	Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07/1 in HEL cells assessed as inhibition of viral cytopathicity Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07/1 in HEL cells assessed as inhibition of viral cytopathicity	[PMID: 18835175]
HEL	CC₅₀	733 μM Compound: ACV, acyclovir	Cytotoxicity against human HEL cells assessed as reduction of growth after 3 days Cytotoxicity against human HEL cells assessed as reduction of growth after 3 days	[PMID: 19226140]
HEL	EC₅₀	1 μM Compound: ACV, acyclovir	Antiviral activity against HPMPA-resistant HCMV AD169 clone 2 mutant infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against HPMPA-resistant HCMV AD169 clone 2 mutant infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	1.1 μM Compound: ACV, acyclovir	Antiviral activity against thymidine kinase expressing Varicella zoster virus Oka infected in human HEL cells assessed reduction in viral plaque formation Antiviral activity against thymidine kinase expressing Varicella zoster virus Oka infected in human HEL cells assessed reduction in viral plaque formation	[PMID: 19226140]
HEL	EC₅₀	125 μM Compound: ACV, acyclovir	Antiviral activity against PMEDAP-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against PMEDAP-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	15 μM Compound: ACV, acyclovir	Antiviral activity against wild type HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against wild type HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	176 μM Compound: ACV, acyclovir	Antiviral activity against foscarnet-resistant HCMV AD169 clone C infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against foscarnet-resistant HCMV AD169 clone C infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	200 μM Compound: ACV, acyclovir	Antiviral activity against acyclovir-resistant HCMV AD169 clone 1 infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against acyclovir-resistant HCMV AD169 clone 1 infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	4.3 μM Compound: ACV, acyclovir	Antiviral activity against ganciclovir-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against ganciclovir-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	7.5 μM Compound: ACV, acyclovir	Antiviral activity against wild type HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against wild type HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	7.6 μM Compound: ACV, acyclovir	Antiviral activity against cidofovir HCMV AD169 clone 5 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against cidofovir HCMV AD169 clone 5 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19226140]
HEL	EC₅₀	72 μM Compound: ACV, acyclovir	Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in human HEL cells assessed reduction in viral plaque formation Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in human HEL cells assessed reduction in viral plaque formation	[PMID: 19226140]
HEL	CC₅₀	782 μM Compound: 1a, ACV	Cytotoxicity against human HEL cells assessed as reduction in cell growth after 3 days Cytotoxicity against human HEL cells assessed as reduction in cell growth after 3 days	[PMID: 19339082]
HEL	EC₅₀	1.8 μM Compound: 1a, ACV	Antiviral activity against Varicella zoster virus OKA infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days Antiviral activity against Varicella zoster virus OKA infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days	[PMID: 19339082]
HEL	EC₅₀	178 μM Compound: 1a, ACV	Antiviral activity against human cytomegalovirus AD169 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection Antiviral activity against human cytomegalovirus AD169 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection	[PMID: 19339082]
HEL	EC₅₀	2 μM Compound: 1a, ACV	Antiviral activity against Varicella zoster virus YS infected in human HEL cells assessed as inhibition of virus induced cytopathicity after 5 days Antiviral activity against Varicella zoster virus YS infected in human HEL cells assessed as inhibition of virus induced cytopathicity after 5 days	[PMID: 19339082]
HEL	EC₅₀	45 μM Compound: 1a, ACV	Antiviral activity against human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection Antiviral activity against human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection	[PMID: 19339082]
HEL	EC₅₀	62.2 μM Compound: 1a, ACV	Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days	[PMID: 19339082]
HEL	EC₅₀	0.2 μM Compound: 1, ACV	Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19645484]
HEL	EC₅₀	0.4 μM Compound: 1, ACV	Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19645484]
HEL	EC₅₀	50 μM Compound: 1, ACV	Antiviral activity against acyclovir 5-monophosphate-resistant thymidine kinase-deficient HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against acyclovir 5-monophosphate-resistant thymidine kinase-deficient HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 19645484]
HEL	CC₅₀	1778 μM Compound: Acyclovir	Cytotoxicity against HEL cells assessed as reduction of cell growth Cytotoxicity against HEL cells assessed as reduction of cell growth	[PMID: 20064723]
HEL	EC₅₀	0.84 μM Compound: Acyclovir	Antiviral activity against thymidine kinase expressing Varicella Zoster Virus OKA infected in HEL cells assessed as reduction of viral plaque formation Antiviral activity against thymidine kinase expressing Varicella Zoster Virus OKA infected in HEL cells assessed as reduction of viral plaque formation	[PMID: 20064723]
HEL	EC₅₀	26.7 μM Compound: Acyclovir	Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in HEL cells assessed as reduction of viral plaque formation Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in HEL cells assessed as reduction of viral plaque formation	[PMID: 20064723]
HEL	EC₅₀	3.3 μM Compound: Acyclovir	Antiviral activity against VZV OKA expressing thymidine kinase infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 5 days Antiviral activity against VZV OKA expressing thymidine kinase infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 5 days	[PMID: 21128666]
HEL	EC₅₀	62 μM Compound: Acyclovir	Antiviral activity against thymidine kinase-deficient VZV 07/1 infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 5 days Antiviral activity against thymidine kinase-deficient VZV 07/1 infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 5 days	[PMID: 21128666]
HEL	CC₅₀	>130 μM Compound: Acyclovir	Cytotoxicity against HEL cells after 3 days by coulter counter analysis Cytotoxicity against HEL cells after 3 days by coulter counter analysis	[PMID: 21232828]
HEL	EC₅₀	>250 μM Compound: Acyclovir	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 21232828]
HEL	EC₅₀	0.2 μM Compound: Acyclovir	Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 21232828]
HEL	EC₅₀	0.4 μM Compound: Acyclovir	Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 21232828]
HEL	EC₅₀	1 μM Compound: Acyclovir	Antiviral activity against VZV OKA expressing thymidine kinase infected in HEL cells assessed as inhibition of plaque formation Antiviral activity against VZV OKA expressing thymidine kinase infected in HEL cells assessed as inhibition of plaque formation	[PMID: 21232828]
HEL	EC₅₀	10 μM Compound: Acyclovir	Antiviral activity against thymidine kinase deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against thymidine kinase deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 21232828]
HEL	EC₅₀	16.5 μM Compound: Acyclovir	Antiviral activity against VZV 07-1 infected in HEL cells assessed as inhibition of plaque formation Antiviral activity against VZV 07-1 infected in HEL cells assessed as inhibition of plaque formation	[PMID: 21232828]
HEL	CC₅₀	1421 μM Compound: Acyclovir	Cytotoxicity against human HEL cells assessed as growth inhibition after 3 days by coulter counter Cytotoxicity against human HEL cells assessed as growth inhibition after 3 days by coulter counter	[PMID: 21565516]
HEL	EC₅₀	>250 μM Compound: Acyclovir	Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
HEL	EC₅₀	0.23 μM Compound: Acyclovir	Antiviral activity against Human herpesvirus 2 G infected in HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against Human herpesvirus 2 G infected in HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
HEL	EC₅₀	0.27 μM Compound: Acyclovir	Antiviral activity against Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
HEL	EC₅₀	27.1 μM Compound: Acyclovir	Antiviral activity against acyclovir-resistant Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against acyclovir-resistant Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
HEL	EC₅₀	3 μM Compound: Acyclovir	Antiviral activity against VZV OKA infected in HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against VZV OKA infected in HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
HEL	EC₅₀	69.3 μM Compound: Acyclovir	Antiviral activity against VZV 07/1 infected in HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against VZV 07/1 infected in HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
HEL	CC₅₀	>400 μM Compound: Acyclovir	Cytotoxicity against human HEL cells by colorimetric formazan-based MTS assay Cytotoxicity against human HEL cells by colorimetric formazan-based MTS assay	[PMID: 21696963]
HEL	EC₅₀	>250 μM Compound: Acyclovir	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis	[PMID: 21696963]
HEL	EC₅₀	0.4 μM Compound: Acyclovir	Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis	[PMID: 21696963]
HEL	EC₅₀	0.4 μM Compound: Acyclovir	Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis	[PMID: 21696963]
HEL	EC₅₀	1.4 μM Compound: Acyclovir	Antiviral activity against Varicella-zoster virus OKA expressing thymidine kinase infected in human HEL cells assessed as reduction in the virus plaque formation Antiviral activity against Varicella-zoster virus OKA expressing thymidine kinase infected in human HEL cells assessed as reduction in the virus plaque formation	[PMID: 21696963]
HEL	EC₅₀	111 μM Compound: Acyclovir	Antiviral activity against thymidine kinase-deficient Varicella-zoster virus YS/R infected in human HEL cells assessed as reduction in the virus plaque formation Antiviral activity against thymidine kinase-deficient Varicella-zoster virus YS/R infected in human HEL cells assessed as reduction in the virus plaque formation	[PMID: 21696963]
HEL	EC₅₀	4.9 μM Compound: Acyclovir	Antiviral activity against Varicella-zoster virus YS expressing thymidine kinase infected in human HEL cells assessed as reduction in the virus plaque formation Antiviral activity against Varicella-zoster virus YS expressing thymidine kinase infected in human HEL cells assessed as reduction in the virus plaque formation	[PMID: 21696963]
HEL	EC₅₀	43 μM Compound: Acyclovir	Antiviral activity against thymidine kinase-deficient Varicella-zoster virus 07-1 infected in human HEL cells assessed as reduction in the virus plaque formation Antiviral activity against thymidine kinase-deficient Varicella-zoster virus 07-1 infected in human HEL cells assessed as reduction in the virus plaque formation	[PMID: 21696963]
HEL	EC₅₀	50 μM Compound: Acyclovir	Antiviral activity against acyclovir-resistant TK-deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis Antiviral activity against acyclovir-resistant TK-deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis	[PMID: 21696963]
HEL	CC₅₀	1338 μM Compound: Acyclovir	Cytotoxicity against human HEL cells after 3 days by coulter counter Cytotoxicity against human HEL cells after 3 days by coulter counter	[PMID: 21745746]
HEL	EC₅₀	>250 μM Compound: Acyclovir	Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
HEL	EC₅₀	>250 μM Compound: Acyclovir	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
HEL	EC₅₀	>250 μM Compound: Acyclovir	Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
HEL	EC₅₀	0.2 μM Compound: Acyclovir	Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
HEL	EC₅₀	0.4 μM Compound: Acyclovir	Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
HEL	EC₅₀	0.49 μM Compound: Acyclovir	Antiviral activity against VSV OKA expressing thymidine kinase infected in HEL cells assessed as reduction of virus plaque formation after 4 days Antiviral activity against VSV OKA expressing thymidine kinase infected in HEL cells assessed as reduction of virus plaque formation after 4 days	[PMID: 22459876]
HEL	EC₅₀	26.6 μM Compound: Acyclovir	Antiviral activity against thymidine kinase-deficient VSV 07-1 infected in HEL cells assessed as reduction of virus plaque formation after 4 days Antiviral activity against thymidine kinase-deficient VSV 07-1 infected in HEL cells assessed as reduction of virus plaque formation after 4 days	[PMID: 22459876]
HEL	CC₅₀	470 μM Compound: Acyclovir	Cytostatic against human HEL cells assessed as reduction in cell growth after 3 days by coulter counter Cytostatic against human HEL cells assessed as reduction in cell growth after 3 days by coulter counter	[PMID: 22578783]
HEL	EC₅₀	2.18 μM Compound: Acyclovir	Antiviral activity against thymidine kinase-positive Varicella-zoster virus YS infected in HEL cells assessed as reduction in virus-induced cytopathicity Antiviral activity against thymidine kinase-positive Varicella-zoster virus YS infected in HEL cells assessed as reduction in virus-induced cytopathicity	[PMID: 22578783]
HEL	EC₅₀	2.5 μM Compound: Acyclovir	Antiviral activity against thymidine kinase-positive Varicella-zoster virus OKA infected in HEL cells assessed as reduction in virus-induced cytopathicity Antiviral activity against thymidine kinase-positive Varicella-zoster virus OKA infected in HEL cells assessed as reduction in virus-induced cytopathicity	[PMID: 22578783]
HEL	EC₅₀	92 μM Compound: Acyclovir	Antiviral activity against thymidine kinase-deficient Varicella-zoster virus 07/1 infected in HEL cells assessed as reduction in virus-induced cytopathicity Antiviral activity against thymidine kinase-deficient Varicella-zoster virus 07/1 infected in HEL cells assessed as reduction in virus-induced cytopathicity	[PMID: 22578783]
HEL	CC₅₀	918 μM Compound: Acyclovir	Cytotoxicity against HEL cells assessed as effect on cell growth incubated for 3 days by Coulter counter assay Cytotoxicity against HEL cells assessed as effect on cell growth incubated for 3 days by Coulter counter assay	[PMID: 22858222]
HEL	EC₅₀	0.38 μM Compound: Acyclovir	Antiviral activity against HSV2 G infected in HEL cells by viral CPE assay Antiviral activity against HSV2 G infected in HEL cells by viral CPE assay	[PMID: 22858222]
HEL	EC₅₀	0.53 μM Compound: Acyclovir	Antiviral activity against HSV1 KOS infected in HEL cells by viral CPE assay Antiviral activity against HSV1 KOS infected in HEL cells by viral CPE assay	[PMID: 22858222]
HEL	EC₅₀	1.64 μM Compound: Acyclovir	Antiviral activity against thymidine kinase positive VZV OKa infected in HEL cells by plaque formation assay Antiviral activity against thymidine kinase positive VZV OKa infected in HEL cells by plaque formation assay	[PMID: 22858222]
HEL	EC₅₀	2.84 μM Compound: Acyclovir	Antiviral activity against thymidine kinase positive VZV YS infected in HEL cells by plaque formation assay Antiviral activity against thymidine kinase positive VZV YS infected in HEL cells by plaque formation assay	[PMID: 22858222]
HEL	EC₅₀	37 μM Compound: Acyclovir	Antiviral activity against thymidine kinase negative VZV YS/R infected in HEL cells by plaque formation assay Antiviral activity against thymidine kinase negative VZV YS/R infected in HEL cells by plaque formation assay	[PMID: 22858222]
HEL	EC₅₀	54 μM Compound: Acyclovir	Antiviral activity against thymidine kinase negative VZV 07/01 infected in HEL cells by plaque formation assay Antiviral activity against thymidine kinase negative VZV 07/01 infected in HEL cells by plaque formation assay	[PMID: 22858222]
HEL	EC₅₀	>1000 μM Compound: Acyclovir	Antiviral activity against Vaccinia virus Lederie infected in HEL cells by viral CPE assay Antiviral activity against Vaccinia virus Lederie infected in HEL cells by viral CPE assay	[PMID: 22858222]
HEL	EC₅₀	≥212 μM Compound: Acyclovir	Antiviral activity against thymidine kinase negative and ACV resistant HSV1 KOS infected in HEL cells by viral CPE assay Antiviral activity against thymidine kinase negative and ACV resistant HSV1 KOS infected in HEL cells by viral CPE assay	[PMID: 22858222]
HEL	CC₅₀	134 μM Compound: Acyclovir	Cytotoxicity against HEL after 3 days Cytotoxicity against HEL after 3 days	[PMID: 23047229]
HEL	EC₅₀	15 μM Compound: Acyclovir	Antiviral activity against thymidine kinase-deficient VZV 07/1 infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days Antiviral activity against thymidine kinase-deficient VZV 07/1 infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days	[PMID: 23047229]
HEL	EC₅₀	2.7 μM Compound: Acyclovir	Antiviral activity against VZV OKA expressing thymidine kinase infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 3 days Antiviral activity against VZV OKA expressing thymidine kinase infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 3 days	[PMID: 23047229]
HEL	EC₅₀	>250 μM Compound: Acyclovir	Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 23099097]
HEL	EC₅₀	>=250 μM Compound: Acyclovir	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 23099097]
HEL	EC₅₀	0.14 μM Compound: Acyclovir	Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 23099097]
HEL	EC₅₀	0.14 μM Compound: Acyclovir	Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 23099097]
HEL	EC₅₀	44 μM Compound: Acyclovir	Antiviral activity against thymidine kinase deficient and acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against thymidine kinase deficient and acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 23099097]
HEL	EC₅₀	>250 μM Compound: Acyclovir	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis	[PMID: 23603046]
HEL	EC₅₀	0.08 μM Compound: Acyclovir	Antiviral activity against Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis Antiviral activity against Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis	[PMID: 23603046]
HEL	EC₅₀	0.08 μM Compound: Acyclovir	Antiviral activity against Human simplex virus 2 G infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis Antiviral activity against Human simplex virus 2 G infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis	[PMID: 23603046]
HEL	EC₅₀	29 μM Compound: Acyclovir	Antiviral activity against thymidine kinase-deficient Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis Antiviral activity against thymidine kinase-deficient Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis	[PMID: 23603046]
HEL	EC₅₀	>250 μM Compound: acyclovir	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 23811093]
HEL	EC₅₀	>250 μM Compound: acyclovir	Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 23811093]
HEL	EC₅₀	0.026 μM Compound: acyclovir	Antiviral activity against TK-positive Varicella-zoster virus OKA infected in human HEL cells assessed as reduction of plaque formation Antiviral activity against TK-positive Varicella-zoster virus OKA infected in human HEL cells assessed as reduction of plaque formation	[PMID: 23811093]
HEL	EC₅₀	0.2 μM Compound: acyclovir	Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 23811093]
HEL	EC₅₀	0.4 μM Compound: acyclovir	Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 23811093]
HEL	EC₅₀	112 μM Compound: acyclovir	Antiviral activity against TK-negative Herpes simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against TK-negative Herpes simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 23811093]
HEL	EC₅₀	143.6 μM Compound: acyclovir	Antiviral activity against TK-positive Varicella-zoster virus 07-1 infected in human HEL cells assessed as reduction of plaque formation Antiviral activity against TK-positive Varicella-zoster virus 07-1 infected in human HEL cells assessed as reduction of plaque formation	[PMID: 23811093]
HEL	EC₅₀	>250 μM Compound: Acyclovir	Antiviral activity against Vaccinia virus Lederle infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity Antiviral activity against Vaccinia virus Lederle infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity	[PMID: 23911856]
HEL	EC₅₀	>250 μM Compound: Acyclovir	Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity	[PMID: 23911856]
HEL	EC₅₀	0.2 μM Compound: Acyclovir	Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity	[PMID: 23911856]
HEL	EC₅₀	0.2 μM Compound: Acyclovir	Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity	[PMID: 23911856]
HEL	EC₅₀	112 μM Compound: Acyclovir	Antiviral activity against thymidine kinase negative acyclovir positive Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity Antiviral activity against thymidine kinase negative acyclovir positive Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity	[PMID: 23911856]
HEL	EC₅₀	2.1 μM Compound: Acyclovir	Antiviral activity against thymidine kinase positive Varicella-zoster virus OKA infected in human HEL cells assessed as reduction in virus plaque formation Antiviral activity against thymidine kinase positive Varicella-zoster virus OKA infected in human HEL cells assessed as reduction in virus plaque formation	[PMID: 23911856]
HEL	EC₅₀	26 μM Compound: Acyclovir	Antiviral activity against thymidine kinase negative Varicella-zoster virus 07-1 infected in human HEL cells assessed as reduction in the virus plaque formation Antiviral activity against thymidine kinase negative Varicella-zoster virus 07-1 infected in human HEL cells assessed as reduction in the virus plaque formation	[PMID: 23911856]
HEL	EC₅₀	0.2 μM Compound: 10, ACV	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 24177359]
HEL	EC₅₀	0.23 μM Compound: 10, ACV	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 24177359]
HEL	EC₅₀	23 μM Compound: 10, ACV	Antiviral activity against acyclovir-resistant thymidine kinase-deficient Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against acyclovir-resistant thymidine kinase-deficient Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 24177359]
HEL	EC₅₀	0.32 μM Compound: 1, ACV, Acyclovir	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 24185376]
HEL	EC₅₀	0.5 μM Compound: 1, ACV, Acyclovir	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 24185376]
HEL	EC₅₀	18 μM Compound: 1, ACV, Acyclovir	Antiviral activity against thymidine kinase-deficient ACV-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against thymidine kinase-deficient ACV-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 24185376]
HEL	CC₅₀	440 μM Compound: Acyclovir	Cytotoxicity against HEL cells assessed as reduction in cell growth after 3 to 5 days by Coulter counting analysis Cytotoxicity against HEL cells assessed as reduction in cell growth after 3 to 5 days by Coulter counting analysis	[PMID: 24690527]
HEL	EC₅₀	0.1 μM Compound: Acyclovir	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction in virus-induced cytopathicity after 3 days Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction in virus-induced cytopathicity after 3 days	[PMID: 24690527]
HEL	EC₅₀	0.2 μM Compound: Acyclovir	Antiviral activity against thymidine kinase-positive Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathicity after 3 days Antiviral activity against thymidine kinase-positive Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathicity after 3 days	[PMID: 24690527]
HEL	EC₅₀	140 μM Compound: Acyclovir	Antiviral activity against thymidine kinase-deficient Varicella zoster virus 07-1 infected in HEL cells assessed as reduction in viral plaque formation after 5 days Antiviral activity against thymidine kinase-deficient Varicella zoster virus 07-1 infected in HEL cells assessed as reduction in viral plaque formation after 5 days	[PMID: 24690527]
HEL	EC₅₀	2.6 μM Compound: Acyclovir	Antiviral activity against thymidine kinase-positive Varicella zoster virus Oka infected in HEL cells assessed as reduction in viral plaque formation after 5 days Antiviral activity against thymidine kinase-positive Varicella zoster virus Oka infected in HEL cells assessed as reduction in viral plaque formation after 5 days	[PMID: 24690527]
HEL	EC₅₀	50 μM Compound: Acyclovir	Antiviral activity against thymidine kinase-deficient ACV-resistant Herpes simplex virus 1 B-2006 infected in HEL cells assessed as reduction in virus-induced cytopathicity after 3 days Antiviral activity against thymidine kinase-deficient ACV-resistant Herpes simplex virus 1 B-2006 infected in HEL cells assessed as reduction in virus-induced cytopathicity after 3 days	[PMID: 24690527]
HEL	EC₅₀	>250 μM Compound: Acyclovir	Antiviral activity against Vaccinia virus infected in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Vaccinia virus infected in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 26001344]
HEL	EC₅₀	0.08 μM Compound: Acyclovir	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 26001344]
HEL	EC₅₀	0.2 μM Compound: Acyclovir	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 26001344]
HEL	EC₅₀	1.5 μM Compound: Acyclovir	Antiviral activity against Varicella-zoster virus expressing thymidine kinase infected in HEL cells assessed as reduction of virus-induced plaque formation Antiviral activity against Varicella-zoster virus expressing thymidine kinase infected in HEL cells assessed as reduction of virus-induced plaque formation	[PMID: 26001344]
HEL	EC₅₀	2 μM Compound: Acyclovir	Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 26001344]
HEL	EC₅₀	33 μM Compound: Acyclovir	Antiviral activity against thymidine kinase-deficient Varicella-zoster virus infected in HEL cells assessed as reduction of virus-induced plaque formation Antiviral activity against thymidine kinase-deficient Varicella-zoster virus infected in HEL cells assessed as reduction of virus-induced plaque formation	[PMID: 26001344]
HEL	CC₅₀	>440 μM Compound: Acyclovir	Cytotoxicity against Varicella zoster virus infected HEL cells assessed as cell growth inhibition incubated for 3 days by coulter counter method Cytotoxicity against Varicella zoster virus infected HEL cells assessed as cell growth inhibition incubated for 3 days by coulter counter method	[PMID: 26443550]
HEL	EC₅₀	1.82 μM Compound: Acyclovir	Antiviral activity against thymidine kinase-deficient Varicella zoster virus Oka infected in HEL cells assessed as reduction in viral plaque formation Antiviral activity against thymidine kinase-deficient Varicella zoster virus Oka infected in HEL cells assessed as reduction in viral plaque formation	[PMID: 26443550]
HEL	EC₅₀	54.5 μM Compound: Acyclovir	Antiviral activity against thymidine kinase-positive Varicella zoster virus 07-1 infected in HEL cells assessed as reduction in viral plaque formation Antiviral activity against thymidine kinase-positive Varicella zoster virus 07-1 infected in HEL cells assessed as reduction in viral plaque formation	[PMID: 26443550]
HEL	EC₅₀	27 μM Compound: Acyclovir	Antiviral activity against TK-deficient Varicella-zoster virus infected in HEL cells Antiviral activity against TK-deficient Varicella-zoster virus infected in HEL cells	[PMID: 27128178]
HEL	CC₅₀	191 μM Compound: Acyclovir	Cytotoxicity against HEL cells assessed as growth inhibition after 3 days by coulter counter method Cytotoxicity against HEL cells assessed as growth inhibition after 3 days by coulter counter method	[PMID: 27639368]
HEL	EC₅₀	0.08 μM Compound: Acyclovir	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation	[PMID: 27639368]
HEL	EC₅₀	0.2 μM Compound: Acyclovir	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus plaque formation Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus plaque formation	[PMID: 27639368]
HEL	EC₅₀	1.9 μM Compound: Acyclovir	Antiviral activity against thymidine Kinase expressing Varicella-Zoster virus OKA infected in HEL cells assessed as inhibition of virus plaque formation Antiviral activity against thymidine Kinase expressing Varicella-Zoster virus OKA infected in HEL cells assessed as inhibition of virus plaque formation	[PMID: 27639368]
HEL	EC₅₀	112 μM Compound: Acyclovir	Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation	[PMID: 27639368]
HEL	EC₅₀	26 μM Compound: Acyclovir	Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07-1 infected in HEL cells assessed as inhibition of virus plaque formation Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07-1 infected in HEL cells assessed as inhibition of virus plaque formation	[PMID: 27639368]
HEL	CC₅₀	440 μM Compound: Acyclovir	Cytotoxicity against HEL cells infected with Varicella-Zoster virus assessed as growth inhibition Cytotoxicity against HEL cells infected with Varicella-Zoster virus assessed as growth inhibition	[PMID: 27750154]
HEL	CC₅₀	>444 μM Compound: Acyclovir	Cytotoxic activity against HEL cells assessed as reduction in cell proliferation after 3 days by coulter counting method Cytotoxic activity against HEL cells assessed as reduction in cell proliferation after 3 days by coulter counting method	[PMID: 28682067]
HEL	CC₅₀	>440 μM Compound: Acyclovir	Cytotoxicity against HEL cells assessed as reduction in cell growth after 3 days by coulter counter method Cytotoxicity against HEL cells assessed as reduction in cell growth after 3 days by coulter counter method	[PMID: 28757102]
HEL	CC₅₀	787 μM Compound: ACV	Cytotoxicity against human HEL cells assessed as cell growth inhibition by cell counting method Cytotoxicity against human HEL cells assessed as cell growth inhibition by cell counting method	[PMID: 28829913]
HEL	CC₅₀	>444 μM Compound: Acyclovir	Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method	[PMID: 29268134]
HEL	CC₅₀	>440 μM Compound: Acyclovir	Cytostatic activity against HEL cells after 3 days by Coulter counting method Cytostatic activity against HEL cells after 3 days by Coulter counting method	[PMID: 29407990]
HEL	CC₅₀	>444 μM Compound: Acyclovir	Cytostatic activity against HEL cells after 3 days by Coulter counting method Cytostatic activity against HEL cells after 3 days by Coulter counting method	[PMID: 29550734]
HEL	CC₅₀	>444 μM Compound: Acyclovir	Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method	[PMID: 29670705]
HEL	CC₅₀	>440 μM Compound: Acyclovir	Cytostatic activity against human HEL cells after 3 days by coulter counter method Cytostatic activity against human HEL cells after 3 days by coulter counter method	[PMID: 29945100]
HEL	EC₅₀	>250 μM Compound: Acyclovir	Antiviral activity against acyclovir-resistant thymidine kinase negative Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against acyclovir-resistant thymidine kinase negative Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
HEL	EC₅₀	>250 μM Compound: Acyclovir	Antiviral activity against Vaccinia virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Vaccinia virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
HEL	EC₅₀	>250 μM Compound: Acyclovir	Antiviral activity against Vesicular stomatitis virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Vesicular stomatitis virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
HEL	EC₅₀	0.7 μM Compound: Acyclovir	Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
HEL	EC₅₀	1 μM Compound: Acyclovir	Antiviral activity against Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
HEL	CC₅₀	>444 μM Compound: Acyclovir	Cytotoxicity against human HEL cells assessed as reduction in cell proliferation incubated for 3 days by Coulter counter method Cytotoxicity against human HEL cells assessed as reduction in cell proliferation incubated for 3 days by Coulter counter method	[PMID: 32676147]
HEL	EC₅₀	42.7 μM Compound: Acyclovir	Antiviral activity against thymidine kinase deficient Varicella zoster virus 07-1 infected in human HEL cells assessed as reduction in plaque formation measured after 5 days Antiviral activity against thymidine kinase deficient Varicella zoster virus 07-1 infected in human HEL cells assessed as reduction in plaque formation measured after 5 days	[PMID: 32676147]
HEL	EC₅₀	7.06 μM Compound: Acyclovir	Antiviral activity against thymidine kinase positive Varicella zoster virus OKA infected in human HEL cells assessed as reduction in plaque formation measured after 5 days Antiviral activity against thymidine kinase positive Varicella zoster virus OKA infected in human HEL cells assessed as reduction in plaque formation measured after 5 days	[PMID: 32676147]
HEL	CC₅₀	>300 μM Compound: Acyclovir	Cytotoxicity against human HEL cells assessed as reduction in cell growth incubated for 3 days by coulter counter method Cytotoxicity against human HEL cells assessed as reduction in cell growth incubated for 3 days by coulter counter method	[PMID: 33039724]
HEL	CC₅₀	424 μM Compound: Acyclovir	Cytotoxicity against human HEL cells assessed as reduce in cell growth incubated for 3 days by coulter counter analysis Cytotoxicity against human HEL cells assessed as reduce in cell growth incubated for 3 days by coulter counter analysis	[PMID: 33479570]
HEL	CC₅₀	>300 μM Compound: Acyclovir	Cytotoxicity against human HEL cells assessed as reduction in cell viability measured after 3 days by beckman coulter counting method Cytotoxicity against human HEL cells assessed as reduction in cell viability measured after 3 days by beckman coulter counting method	[PMID: 33894564]
HEL	CC₅₀	>444.03 μM Compound: Acyclovir	Cytotoxicity against human HEL cells assessed as reduction in cell growth measured after 3 days by coulter counting method Cytotoxicity against human HEL cells assessed as reduction in cell growth measured after 3 days by coulter counting method	[PMID: 35754374]
HEL	CC₅₀	470 μM Compound: Acyclovir	Cytostatic activity against human HEL cells assessed as reduction in cell growth measured after 24 hrs Cytostatic activity against human HEL cells assessed as reduction in cell growth measured after 24 hrs	[PMID: 38643669]
HEL	CC₅₀	>200 μg/mL Compound: L-BVDU	Tested for the cytotoxic concentration, required to reduce cell growth by 50% in human embryonic lung (HEL) cells. Tested for the cytotoxic concentration, required to reduce cell growth by 50% in human embryonic lung (HEL) cells.	[PMID: 7877148]
HEL	IC₅₀	0.04 μg/mL Compound: L-BVDU	Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain OKA plaque formation by 50%. Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain OKA plaque formation by 50%.	[PMID: 7877148]
HEL	IC₅₀	0.15 μg/mL Compound: L-BVDU	Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain YS plaque formation by 50% Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain YS plaque formation by 50%	[PMID: 7877148]
HEL	IC₅₀	15 μg/mL Compound: L-BVDU	Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain Davis plaque formation by 50%. Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain Davis plaque formation by 50%.	[PMID: 7877148]
HEL	IC₅₀	20 μg/mL Compound: L-BVDU	Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain AD-169 plaque formation by 50%. Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain AD-169 plaque formation by 50%.	[PMID: 7877148]
HEL	IC₅₀	3 μg/mL Compound: L-BVDU	Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain 07/1 plaque formation by 50%. Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain 07/1 plaque formation by 50%.	[PMID: 7877148]
HEL	IC₅₀	5 μg/mL Compound: L-BVDU	Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain YS/R plaque formation by 50%. Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain YS/R plaque formation by 50%.	[PMID: 7877148]
HEL	IC₅₀	>200 μg/mL Compound: ACV	Tested for inhibitory effect on RNA virus cell growth in HEL cell line Tested for inhibitory effect on RNA virus cell growth in HEL cell line	[PMID: 8246242]
HEL	IC₅₀	0.1 μg/mL Compound: ACV	Tested for inhibitory effect on DNA virus VZV (Oka) in HEL cell line Tested for inhibitory effect on DNA virus VZV (Oka) in HEL cell line	[PMID: 8246242]
HEL	IC₅₀	0.1 μg/mL Compound: ACV	Tested for inhibitory effect on DNA virus VZV (YS) in HEL cell line Tested for inhibitory effect on DNA virus VZV (YS) in HEL cell line	[PMID: 8246242]
HEL	IC₅₀	22 μg/mL Compound: ACV	Tested for inhibitory effect on DNA virus CMV (Davis) in HEL cell line Tested for inhibitory effect on DNA virus CMV (Davis) in HEL cell line	[PMID: 8246242]
HEL	IC₅₀	26 μg/mL Compound: ACV	Tested for inhibitory effect on DNA virus CMV (AD-169) in HEL cell line Tested for inhibitory effect on DNA virus CMV (AD-169) in HEL cell line	[PMID: 8246242]
HEL	IC₅₀	4 μg/mL Compound: ACV	Tested for inhibitory effect on DNA virus TK-VZV (07/1) in HEL cell line Tested for inhibitory effect on DNA virus TK-VZV (07/1) in HEL cell line	[PMID: 8246242]
HEL	IC₅₀	5 μg/mL Compound: ACV	Tested for inhibitory effect on DNA virus TK-VZV (YS/R) in HEL cell line Tested for inhibitory effect on DNA virus TK-VZV (YS/R) in HEL cell line	[PMID: 8246242]
HEL	IC₅₀	0.18 μg/mL Compound: Acyclovir	Antiviral activity in TK+ varicella zoster virus (VZV) OKA strain in HEL cell culture Antiviral activity in TK+ varicella zoster virus (VZV) OKA strain in HEL cell culture	[PMID: 8831773]
HEL	IC₅₀	0.35 μg/mL Compound: Acyclovir	Antiviral activity in TK+ varicella zoster virus (VZV) YS strain in HEL cell culture Antiviral activity in TK+ varicella zoster virus (VZV) YS strain in HEL cell culture	[PMID: 8831773]
HEL	IC₅₀	11 μg/mL Compound: Acyclovir	Antiviral activity in TK+ varicella zoster virus (VZV) 07/1 strain in HEL cell culture Antiviral activity in TK+ varicella zoster virus (VZV) 07/1 strain in HEL cell culture	[PMID: 8831773]
HEL	IC₅₀	13 μg/mL Compound: Acyclovir	Antiviral activity against cytomegalovirus (CMV) AD169 strain in HEL cell culture Antiviral activity against cytomegalovirus (CMV) AD169 strain in HEL cell culture	[PMID: 8831773]
HEL	IC₅₀	22 μg/mL Compound: Acyclovir	Antiviral activity in TK+ varicella zoster virus (VZV) YS/R strain in HEL cell culture Antiviral activity in TK+ varicella zoster virus (VZV) YS/R strain in HEL cell culture	[PMID: 8831773]
HEL	ED₅₀	0.14 μg/mL Compound: acyclovir	Antiviral activity against herpes simplex virus-1 VR-3 strain in HEL (human erythroleukemia) cells. Antiviral activity against herpes simplex virus-1 VR-3 strain in HEL (human erythroleukemia) cells.	[PMID: 9216836]
HEL	ED₅₀	0.23 μg/mL Compound: acyclovir	Antiviral activity against herpes simplex virus-2 (HSV-2) Ms strain in HEL (human erythroleukemia) cells. Antiviral activity against herpes simplex virus-2 (HSV-2) Ms strain in HEL (human erythroleukemia) cells.	[PMID: 9216836]
HEL	ED₅₀	2.7 μg/mL Compound: acyclovir	Antiviral activity against varicella zoster virus (VZV) Oka strain in HEL (human erythroleukemia) cells. Antiviral activity against varicella zoster virus (VZV) Oka strain in HEL (human erythroleukemia) cells.	[PMID: 9216836]
HEL	ED₅₀	6.9 μg/mL Compound: acyclovir	Antiviral activity against human cytomegalovirus (HCMV) AD 169 strain HEL (human erythroleukemia) cells. Antiviral activity against human cytomegalovirus (HCMV) AD 169 strain HEL (human erythroleukemia) cells.	[PMID: 9216836]
HEL	IC₅₀	>25 μg/mL Compound: acyclovir	Anti-VZV activity against 07/1 TK- in HEL cells Anti-VZV activity against 07/1 TK- in HEL cells	[PMID: 9836626]
HEL	IC₅₀	>40 μg/mL Compound: acyclovir	Anti-VZV activity against YS/R TK- in HEL cells Anti-VZV activity against YS/R TK- in HEL cells	[PMID: 9836626]
HEL	IC₅₀	0.82 μg/mL Compound: acyclovir	Anti-VZV activity against OKA strain TK+ in HEL cells Anti-VZV activity against OKA strain TK+ in HEL cells	[PMID: 9836626]
HEL	IC₅₀	0.95 μg/mL Compound: acyclovir	Anti-VZV activity against YS TK+ in HEL cells Anti-VZV activity against YS TK+ in HEL cells	[PMID: 9836626]
HEL	CC₅₀	120 μg/mL Compound: Acyclovir	Cytotoxicity against HEL Cytotoxicity against HEL	10.1007/s00044-011-9776-0
HEL	EC₅₀	0.44 μg/mL Compound: Acyclovir	Antiviral activity against thymidine kinase-positive Human herpesvirus 3 infected in HEL cells assessed as inhibition of viral plaque formation Antiviral activity against thymidine kinase-positive Human herpesvirus 3 infected in HEL cells assessed as inhibition of viral plaque formation	10.1007/s00044-011-9776-0
HEL	EC₅₀	23 μg/mL Compound: Acyclovir	Antiviral activity against thymidine kinase-deficient Human herpesvirus 3 infected in HEL cells assessed as inhibition of viral plaque formation Antiviral activity against thymidine kinase-deficient Human herpesvirus 3 infected in HEL cells assessed as inhibition of viral plaque formation	10.1007/s00044-011-9776-0
HEL	CC₅₀	>50 μg/mL Compound: 1 (Acyclovir ACV)	Cytotoxicity (to reduce cell growth) against Varicella-Zoster virus in human embryonic lung (HEL) cells Cytotoxicity (to reduce cell growth) against Varicella-Zoster virus in human embryonic lung (HEL) cells	10.1016/S0960-894X(01)80538-2
HEL	IC₅₀	0.23 μg/mL Compound: 1 (Acyclovir ACV)	Antiviral activity against thymidine kinase-positive (TK+) OKA strain of Varicella zoster virus to reduce plaque formation in human embryonic lung (HEL) cells Antiviral activity against thymidine kinase-positive (TK+) OKA strain of Varicella zoster virus to reduce plaque formation in human embryonic lung (HEL) cells	10.1016/S0960-894X(01)80538-2
HEL	IC₅₀	0.32 μg/mL Compound: 1 (Acyclovir ACV)	Antiviral activity against thymidine kinase-positive (TK+) YS strain of Varicella zoster virus to reduce plaque formation in human embryonic lung (HEL) cells Antiviral activity against thymidine kinase-positive (TK+) YS strain of Varicella zoster virus to reduce plaque formation in human embryonic lung (HEL) cells	10.1016/S0960-894X(01)80538-2
HEL	IC₅₀	22 μg/mL Compound: 1 (Acyclovir ACV)	Antiviral activity against thymidine kinase-negative (TK-) O7/1 strain of Varicella zoster virus to reduce plaque formation in human embryonic lung (HEL) cells Antiviral activity against thymidine kinase-negative (TK-) O7/1 strain of Varicella zoster virus to reduce plaque formation in human embryonic lung (HEL) cells	10.1016/S0960-894X(01)80538-2
HEL	IC₅₀	9 μg/mL Compound: 1 (Acyclovir ACV)	Antiviral activity against thymidine kinase-negative (TK-) YS/R strain of Varicella zoster virus to reduce plaque formation in human embryonic lung (HEL) cells Antiviral activity against thymidine kinase-negative (TK-) YS/R strain of Varicella zoster virus to reduce plaque formation in human embryonic lung (HEL) cells	10.1016/S0960-894X(01)80538-2
HEL	IC₅₀	24 μg/mL Compound: Acyclovir	Antiviral activity was measured against Varicella-Zoster virus (VZV) 07/1 strain in human embryonic lung (HEL) cells Antiviral activity was measured against Varicella-Zoster virus (VZV) 07/1 strain in human embryonic lung (HEL) cells	10.1016/S0960-894X(97)00149-2
HEL	IC₅₀	26 μg/mL Compound: Acyclovir	Antiviral activity was measured against Varicella-Zoster virus (VZV) YS/R strain in human embryonic lung (HEL) cells Antiviral activity was measured against Varicella-Zoster virus (VZV) YS/R strain in human embryonic lung (HEL) cells	10.1016/S0960-894X(97)00149-2
HEL	IC₅₀	>50 μg/mL Compound: Acyclovir	In vitro inhibitory concentration for antiviral activity was tested against HEL cells In vitro inhibitory concentration for antiviral activity was tested against HEL cells	10.1016/S0960-894X(97)00365-X
HEL 299	CC₅₀	>100 μM Compound: 1a	Cytotoxicity against human HEL299 cells after 3 days by MTT assay Cytotoxicity against human HEL299 cells after 3 days by MTT assay	[PMID: 26460883]
HeLa	IC₅₀	0.11 μM Compound: Acyclovir	Ability to inhibit cytopathogenicity of herpes simplex type 1 virus (KOS) in HeLa cell culture Ability to inhibit cytopathogenicity of herpes simplex type 1 virus (KOS) in HeLa cell culture	[PMID: 11356110]
HeLa	IC₅₀	0.19 μM Compound: Acyclovir	Ability to inhibit cytopathogenicity of herpes simplex type 1 virus (G) in HeLa cell culture Ability to inhibit cytopathogenicity of herpes simplex type 1 virus (G) in HeLa cell culture	[PMID: 11356110]
HeLa	IC₅₀	253.64 μM Compound: Acyclovir	Concentration required to cause microscopically visible change or disruption in about 50% of cell sheet of HeLa cells Concentration required to cause microscopically visible change or disruption in about 50% of cell sheet of HeLa cells	[PMID: 11356110]
HeLa	IC₅₀	26.43 μM Compound: Acyclovir	Ability to inhibit cytopathogenicity of thymidine kinase-deficient (TK-) strain of Varicella zoster virus (YS/R) in HeLa cell culture Ability to inhibit cytopathogenicity of thymidine kinase-deficient (TK-) strain of Varicella zoster virus (YS/R) in HeLa cell culture	[PMID: 11356110]
HeLa	IC₅₀	8.71 μM Compound: Acyclovir	Ability to inhibit cytopathogenicity of thymidine kinase-positive(TK+) strain of Varicella zoster virus (YS) in HeLa cell culture Ability to inhibit cytopathogenicity of thymidine kinase-positive(TK+) strain of Varicella zoster virus (YS) in HeLa cell culture	[PMID: 11356110]
HeLa	CC₅₀	>400 μM Compound: Acyclovir (ACV)	Cytotoxic concentration required to inhibit Hel cell growth Cytotoxic concentration required to inhibit Hel cell growth	[PMID: 15109620]
HeLa	CC₅₀	>400 μM Compound: Aciclovir	Cytotoxic concentration required to inhibit Hel cell growth by using DMSO as solvent Cytotoxic concentration required to inhibit Hel cell growth by using DMSO as solvent	[PMID: 15993062]
HeLa	CC₅₀	541 μM Compound: Acyclovir	Cytotoxicity against human HeLa cells assessed as cell viability by colorimetric formazan-based MTS assay Cytotoxicity against human HeLa cells assessed as cell viability by colorimetric formazan-based MTS assay	[PMID: 22459876]
HeLa	IC₅₀	0.1 μg/mL Compound: 1	Inhibition of cytopathogenicity of herpes simplex type 1 virus (HSV-1)(KOS) in Hela cell culture. Inhibition of cytopathogenicity of herpes simplex type 1 virus (HSV-1)(KOS) in Hela cell culture.	[PMID: 7473592]
HeLa	IC₅₀	0.23 μg/mL Compound: 1	Inhibition of cytopathogenicity of herpes simplex type 2 virus(HSV-12(G) in Hela cell culture Inhibition of cytopathogenicity of herpes simplex type 2 virus(HSV-12(G) in Hela cell culture	[PMID: 7473592]
HeLa	IC₅₀	20 μg/mL Compound: 1	Inhibition of cytopathogenicity of Varicella-Zoster virus(VZV)(YS) in Hela cell culture. Inhibition of cytopathogenicity of Varicella-Zoster virus(VZV)(YS) in Hela cell culture.	[PMID: 7473592]
HeLa	IC₅₀	250 μg/mL Compound: 1	Concentration required to cause microscopically visible change or disruption in about 50% of Hela cell sheet. Concentration required to cause microscopically visible change or disruption in about 50% of Hela cell sheet.	[PMID: 7473592]
HeLa	IC₅₀	>200 μM Compound: acyclovir	Inhibition of [3H]thymidine incorporation into the DNA of uninfected HeLa cells Inhibition of [3H]thymidine incorporation into the DNA of uninfected HeLa cells	[PMID: 7752206]
HeLa	IC₅₀	1.9 μM Compound: acyclovir	Inhibition of HSV-1 DNA synthesis in virus-infected HeLa cells Inhibition of HSV-1 DNA synthesis in virus-infected HeLa cells	[PMID: 7752206]
HeLa	CC₅₀	200 μg/mL Compound: Acyclovir	Cytotoxic activity was measured in human embryonic lung cells (HeLa) Cytotoxic activity was measured in human embryonic lung cells (HeLa)	10.1016/S0960-894X(97)00149-2
HEp-2	IC₅₀	25 μg/mL Compound: acyclovir	Antiviral activity against Cox B3 virus in human Hep2 cells assessed as reduction of virus induced cytopathic effect Antiviral activity against Cox B3 virus in human Hep2 cells assessed as reduction of virus induced cytopathic effect	[PMID: 16724853]
HEp-2	EC₅₀	0.26 μg/mL Compound: acyclovir	Antiviral activity against HSV1 infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days Antiviral activity against HSV1 infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days	[PMID: 9599250]
HEp-2	EC₅₀	2.3 μg/mL Compound: acyclovir	Antiviral activity against HSV2 infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days Antiviral activity against HSV2 infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days	[PMID: 9599250]
HEp-2	IC₅₀	>10 μg/mL Compound: acyclovir	Cytotoxicity against HSV2 infected human Hep2 cells after 3 days Cytotoxicity against HSV2 infected human Hep2 cells after 3 days	[PMID: 9599250]
HEp-2	IC₅₀	>67 μg/mL Compound: acyclovir	Cytotoxicity against HSV1 infected human Hep2 cells after 3 days Cytotoxicity against HSV1 infected human Hep2 cells after 3 days	[PMID: 9599250]
HepG2 2.2.15	CC₅₀	630 μM Compound: ACV, Acyclovir	Cytotoxicity against human HepG2.2.15 cells assessed as reduction in number of viable cells after 3 days by MTT assay Cytotoxicity against human HepG2.2.15 cells assessed as reduction in number of viable cells after 3 days by MTT assay	[PMID: 23369536]
HepG2 2.2.15	IC₅₀	>1000 μM Compound: ACV, Acyclovir	Antiviral activity against Hepatitis B virus transfected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion after 6 days by ELISA Antiviral activity against Hepatitis B virus transfected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion after 6 days by ELISA	[PMID: 23369536]
HepG2 2.2.15	IC₅₀	>1000 μM Compound: ACV, Acyclovir	Antiviral activity against Hepatitis B virus transfected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion after 6 days by ELISA Antiviral activity against Hepatitis B virus transfected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion after 6 days by ELISA	[PMID: 23369536]
HFF	EC₅₀	1.1 μM Compound: Acyclovir	Concentration for HSV-1 plaque reduction (VPR) by 50% in HFF cells Concentration for HSV-1 plaque reduction (VPR) by 50% in HFF cells	[PMID: 14584954]
HFF	EC₅₀	1.68 μM Compound: Acyclovir	Concentration for HSV-2 plaque reduction (VPR) by 50% in HFF cells Concentration for HSV-2 plaque reduction (VPR) by 50% in HFF cells	[PMID: 14584954]
HFF	EC₅₀	10.21 μM Compound: Acyclovir	Inhibitory concentration required to reduce HSV-2 induced cytopathogenic effect (CPE) by 50 % in HFF cells Inhibitory concentration required to reduce HSV-2 induced cytopathogenic effect (CPE) by 50 % in HFF cells	[PMID: 14584954]
HFF	EC₅₀	2.22 μM Compound: Acyclovir	Inhibitory concentration required to reduce HSV-1 induced cytopathogenic effect (CPE) by 50 % in HFF cells Inhibitory concentration required to reduce HSV-1 induced cytopathogenic effect (CPE) by 50 % in HFF cells	[PMID: 14584954]
HFF	CC₅₀	>444 μM Compound: acyclovir	Cytotoxicity against HFF cells Cytotoxicity against HFF cells	[PMID: 15615545]
HFF	EC₅₀	1.6 μM Compound: acyclovir	Inhibition of VZV replication in HFF cells by CPE assay Inhibition of VZV replication in HFF cells by CPE assay	[PMID: 15615545]
HFF	CC₅₀	>444 μM Compound: Acyclovir	Cytotoxic concentration to inhibit Herpes simplex virus 1 infected HFF cells Cytotoxic concentration to inhibit Herpes simplex virus 1 infected HFF cells	[PMID: 15634003]
HFF	CC₅₀	>444 μM Compound: Acyclovir	Cytotoxic concentration to inhibit Herpes simplex virus 2 infected HFF cells Cytotoxic concentration to inhibit Herpes simplex virus 2 infected HFF cells	[PMID: 15634003]
HFF	CC₅₀	>444 μM Compound: Acyclovir	Cytotoxic concentration to inhibit replication in HFF cells in cytopathic effect inhibition assay Cytotoxic concentration to inhibit replication in HFF cells in cytopathic effect inhibition assay	[PMID: 15634003]
HFF	EC₅₀	0.9 μM Compound: Acyclovir	Effective concentration required to inhibit herpes simplex virus 1 in HFF cells in cytopathic effect (CPE) assay Effective concentration required to inhibit herpes simplex virus 1 in HFF cells in cytopathic effect (CPE) assay	[PMID: 15634003]
HFF	EC₅₀	1.6 μM Compound: Acyclovir	Effective concentration required to inhibit varicella zoster virus replication in HFF cells Effective concentration required to inhibit varicella zoster virus replication in HFF cells	[PMID: 15634003]
HFF	EC₅₀	6.7 μM Compound: Acyclovir	Effective concentration required to inhibit herpes simplex virus 2 in HFF cells in cytopathic effect (CPE) assay Effective concentration required to inhibit herpes simplex virus 2 in HFF cells in cytopathic effect (CPE) assay	[PMID: 15634003]
HFF	CC₅₀	>100 μM Compound: acyclovir	Toxicity on uninfected human foreskin fibroblast cells determined in microscopic evaluation and quantitative neutral red dye uptake assay Toxicity on uninfected human foreskin fibroblast cells determined in microscopic evaluation and quantitative neutral red dye uptake assay	[PMID: 16134946]
HFF	IC₅₀	>20 μM Compound: acyclovir	Antiviral activity against human cytomegalovirus (Davis strain) grown on human foreskin fibroblast cells determined by reduction in plaque formation upon incubation at 37 degrees C with the compound dissolved in DMSO Antiviral activity against human cytomegalovirus (Davis strain) grown on human foreskin fibroblast cells determined by reduction in plaque formation upon incubation at 37 degrees C with the compound dissolved in DMSO	[PMID: 16134946]
HFF	IC₅₀	8.1 μM Compound: acyclovir	Antiviral activity against Varicella-Zoster virus (Webster strain) grown on human foreskin fibroblast cells determined by vedduction in plaque formation upon incubation at 37 degrees C with the compound dissolved in DMSO until plaque were formed [nd = not Antiviral activity against Varicella-Zoster virus (Webster strain) grown on human foreskin fibroblast cells determined by vedduction in plaque formation upon incubation at 37 degrees C with the compound dissolved in DMSO until plaque were formed [nd = not	[PMID: 16134946]
HFF	EC₅₀	0.03 μM Compound: acyclovir	Inhibition of VZV replication in HFF cells by cytopathic effect assay Inhibition of VZV replication in HFF cells by cytopathic effect assay	[PMID: 17004726]
HFF	EC₅₀	>444 μM Compound: ACV, acyclovir	Antiviral activity against TK- HSV1 DM2.1 in HFF cells after 72 hrs by plaque reduction assay Antiviral activity against TK- HSV1 DM2.1 in HFF cells after 72 hrs by plaque reduction assay	[PMID: 17325220]
HFF	EC₅₀	>444 μM Compound: ACV, acyclovir	Antiviral activity against TK- HSV2 AG3 in HFF cells after 72 hrs by plaque reduction assay Antiviral activity against TK- HSV2 AG3 in HFF cells after 72 hrs by plaque reduction assay	[PMID: 17325220]
HFF	EC₅₀	1.3 μM Compound: ACV, acyclovir	Antiviral activity against TK+ HSV1 E377 in HFF cells after 72 hrs by plaque reduction assay Antiviral activity against TK+ HSV1 E377 in HFF cells after 72 hrs by plaque reduction assay	[PMID: 17325220]
HFF	EC₅₀	3.1 μM Compound: ACV, acyclovir	Antiviral activity against TK- HSV2 MS in HFF cells after 72 hrs by plaque reduction assay Antiviral activity against TK- HSV2 MS in HFF cells after 72 hrs by plaque reduction assay	[PMID: 17325220]
HFF	EC₅₀	8.5 μM Compound: ACV, acyclovir	Antiviral activity against Varicella-Zoster virus Ellen in HFF cells after 10 days by plaque reduction assay Antiviral activity against Varicella-Zoster virus Ellen in HFF cells after 10 days by plaque reduction assay	[PMID: 17325220]
HFF	CC₅₀	>100 μM Compound: acyclovir	Cytotoxicity against HFF cells after 3 days Cytotoxicity against HFF cells after 3 days	[PMID: 17434304]
HFF	IC₅₀	8100 nM Compound: acyclovir	Antiviral activity against VZV Webster in HFF cells by plaque reduction assay Antiviral activity against VZV Webster in HFF cells by plaque reduction assay	[PMID: 17434304]
HFF	IC₅₀	>20000 nM Compound: acyclovir	Antiviral activity against HCMV Davis in HFF cells by plaque reduction assay Antiviral activity against HCMV Davis in HFF cells by plaque reduction assay	[PMID: 17434304]
HFF	CC₅₀	>100 μM Compound: Acyclovir	Cytotoxicity against HFF cells after 3 days by neutral red dye uptake assay Cytotoxicity against HFF cells after 3 days by neutral red dye uptake assay	[PMID: 18595689]
HFF	CC₅₀	>300 μM Compound: Acyclovir	Cytotoxicity against HFF by neutral red uptake assay Cytotoxicity against HFF by neutral red uptake assay	[PMID: 19410465]
HFF	CC₅₀	>444 μM Compound: ACV	Cytotoxicity against HFF after 3 days by MTS assay Cytotoxicity against HFF after 3 days by MTS assay	[PMID: 19770274]
HFF	IC₅₀	>444 μM Compound: ACV	Antiproliferative activity against HFF after 3 days by Coulter counting analysis Antiproliferative activity against HFF after 3 days by Coulter counting analysis	[PMID: 19770274]
HFF	IC₅₀	8100 nM Compound: Acyclovir	Antiviral activity against Varicella zoster virus infected in HFF cells by plaque reduction assay Antiviral activity against Varicella zoster virus infected in HFF cells by plaque reduction assay	[PMID: 20167488]
HFF	IC₅₀	20 μM Compound: Acyclovir	Antiviral activity against Human cytomegalovirus infected in HFF cells by plaque reduction assay Antiviral activity against Human cytomegalovirus infected in HFF cells by plaque reduction assay	[PMID: 20167488]
HFF	CC₅₀	>100 μM Compound: Acyclovir	Cytotoxicity against HFF cells after 3 days by neutral red dye uptake assay Cytotoxicity against HFF cells after 3 days by neutral red dye uptake assay	[PMID: 20403696]
HFF	IC₅₀	>20 μM Compound: Acyclovir	Inhibition of HCMV DNA polymerase infected in HFF cells Inhibition of HCMV DNA polymerase infected in HFF cells	[PMID: 20403696]
HFF	IC₅₀	8.1 μM Compound: Acyclovir	Antiviral activity against VZV Webster infected in HFF cells assessed as reduction in plaque formation Antiviral activity against VZV Webster infected in HFF cells assessed as reduction in plaque formation	[PMID: 20403696]
HFF	CC₅₀	>100 μM Compound: ACV	Cytotoxicity against human HFF cells infected with Varicella-zoster virus Ellen assessed as viable cells by neutral red uptake assay Cytotoxicity against human HFF cells infected with Varicella-zoster virus Ellen assessed as viable cells by neutral red uptake assay	[PMID: 21376429]
HFF	EC₅₀	1.1 μM Compound: ACV	Antiviral activity against Varicella-zoster virus Ellen infected in 1 hr pretreated human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay Antiviral activity against Varicella-zoster virus Ellen infected in 1 hr pretreated human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay	[PMID: 21376429]
HFF	IC₅₀	>100 μM Compound: Acyclovir	Tested for cytotoxic activity against human foreskin fibroblasts (HFF) cells. Tested for cytotoxic activity against human foreskin fibroblasts (HFF) cells.	[PMID: 2163453]
HFF	IC₅₀	>100 μM Compound: acyclovir	Cytotoxic activity against HFF cells. Cytotoxic activity against HFF cells.	[PMID: 2163454]
HFF	IC₅₀	>100 μM Compound: Acyclovir	Tested in vitro for cytotoxicity against the normal human diploid cells (HFF cells). Tested in vitro for cytotoxicity against the normal human diploid cells (HFF cells).	[PMID: 2175356]
HFF	IC₅₀	0.6 μM Compound: ACV	Antiviral activity against HSV1 KOS infected in HFF cells incubated for 3 days by plaque reduction assay Antiviral activity against HSV1 KOS infected in HFF cells incubated for 3 days by plaque reduction assay	[PMID: 21812420]
HFF	CC₅₀	>300 μM Compound: ACV	Cytotoxicity against human HFF cells after 3 to 8 days by crystal voilet staining Cytotoxicity against human HFF cells after 3 to 8 days by crystal voilet staining	[PMID: 22607883]
HFF	IC₅₀	1.9 μM Compound: ACV	Antiviral activity against VZV infected in human HFF cells assessed as reduction in cytopathic effect after 7 days by crystal violet staining Antiviral activity against VZV infected in human HFF cells assessed as reduction in cytopathic effect after 7 days by crystal violet staining	[PMID: 22607883]
HFF	IC₅₀	2.8 μM Compound: ACV	Antiviral activity against HSV-2 infected in human HFF cells assessed as reduction in cytopathic effect after 3 days by crystal violet staining Antiviral activity against HSV-2 infected in human HFF cells assessed as reduction in cytopathic effect after 3 days by crystal violet staining	[PMID: 22607883]
HFF	IC₅₀	2.9 μM Compound: ACV	Antiviral activity against HSV-1 infected in human HFF cells assessed as reduction in cytopathic effect after 3 days by crystal violet staining Antiviral activity against HSV-1 infected in human HFF cells assessed as reduction in cytopathic effect after 3 days by crystal violet staining	[PMID: 22607883]
HFF	CC₅₀	>300 μM Compound: Acyclovir	Cytotoxicity in HFF cells incubated for 7 days by CellTiter-Glo assay Cytotoxicity in HFF cells incubated for 7 days by CellTiter-Glo assay	[PMID: 27933957]
HFF	IC₅₀	>100 μM Compound: 1 (acyclovir)	The compound was tested for cytotoxicity against human foreskin fibroblast cell The compound was tested for cytotoxicity against human foreskin fibroblast cell	[PMID: 2840500]
HFF	IC₅₀	>100 μM Compound: Acyclovir	Cytotoxicity against uninfected human foreskin fibroblast(HFF cells) Cytotoxicity against uninfected human foreskin fibroblast(HFF cells)	[PMID: 2846837]
HFF	IC₅₀	>100 μM Compound: Acyclovir	Cytotoxicity was evaluated against the Human diploid cells (HFF) Cytotoxicity was evaluated against the Human diploid cells (HFF)	[PMID: 2913300]
HFF	CC₅₀	>150 μM Compound: Acyclovir	Cytotoxicity against human HFF cells infected with VZV Ellen virus assessed as reduction in cell viability by cell titer-glo assay Cytotoxicity against human HFF cells infected with VZV Ellen virus assessed as reduction in cell viability by cell titer-glo assay	[PMID: 35754374]
HFF	IC₅₀	>100 μM Compound: acyclovir	Tested for the visual cytotoxicity on HFF cells at the time of human cytomegalovirus (HCMV) plaque enumeration Tested for the visual cytotoxicity on HFF cells at the time of human cytomegalovirus (HCMV) plaque enumeration	[PMID: 8071942]
HFF	EC₅₀	0.04 μM Compound: acyclovir	Inhibitory concentration of the drug against the cytopathic effect for E-377 strain of herpes simplex virus-1 (HSV-1) in human HFF cells Inhibitory concentration of the drug against the cytopathic effect for E-377 strain of herpes simplex virus-1 (HSV-1) in human HFF cells	[PMID: 8394933]
HFF	EC₅₀	0.09 μM Compound: acyclovir	Inhibitory concentration of the drug against the cytopathic effect for MS strain of herpes simplex virus-2 (HSV-2) in human HFF cells Inhibitory concentration of the drug against the cytopathic effect for MS strain of herpes simplex virus-2 (HSV-2) in human HFF cells	[PMID: 8394933]
HFF	EC₅₀	7.1 μM Compound: acyclovir	Inhibitory concentration of the drug against the cytopathic effect for ellen strain of varicella zoster virus-2 (VZV-2) in human HFF cells Inhibitory concentration of the drug against the cytopathic effect for ellen strain of varicella zoster virus-2 (VZV-2) in human HFF cells	[PMID: 8394933]
HFF	IC₅₀	>100 μM Compound: Acyclovir (ACV)	Cytotoxicity produced in human foreskin fibroblasts (HFF) cells estimated by visual scoring of cells unaffected by virus infection. Cytotoxicity produced in human foreskin fibroblasts (HFF) cells estimated by visual scoring of cells unaffected by virus infection.	[PMID: 8784444]
HFF	IC₅₀	2.7 μg/mL Compound: 1a(ACV)	Inhibitory activity against DM625 strain of zoster virus(VZV) by plaque reduction assay in HFF cells Inhibitory activity against DM625 strain of zoster virus(VZV) by plaque reduction assay in HFF cells	[PMID: 9548818]
HSV-2	ED₅₀	3 μg/mL Compound: 1a(ACV)	Antiviral activity against HSV-2 cell line (concentration required to prevent viral cytopathic effect in half of primary rabbit kidney cell cultures) Antiviral activity against HSV-2 cell line (concentration required to prevent viral cytopathic effect in half of primary rabbit kidney cell cultures)	[PMID: 2848125]
Huh-7	CC₅₀	>1000 μM Compound: Acyclovir	Cytotoxicity against mock-infected human HuH7 cells assessed as inhibition of cell survival after 2 days by CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay Cytotoxicity against mock-infected human HuH7 cells assessed as inhibition of cell survival after 2 days by CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay	[PMID: 26048809]
Huh-7	EC₅₀	>1000 μM Compound: Acyclovir	Antiviral activity against MERS-CoV EMC/2012 infected in human HuH7 cells assessed as inhibition of virus-induced cytopathic effect after 2 days by CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay Antiviral activity against MERS-CoV EMC/2012 infected in human HuH7 cells assessed as inhibition of virus-induced cytopathic effect after 2 days by CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay	[PMID: 26048809]
KB	IC₅₀	>100 μM Compound: Acyclovir	Cytotoxicity of compound was determined by assaying cell growth in human neoplastic cell line(KB). Cytotoxicity of compound was determined by assaying cell growth in human neoplastic cell line(KB).	[PMID: 1310744]
KB	CC₅₀	>100 μM Compound: acyclovir	Cytotoxicity against KB cells Cytotoxicity against KB cells	[PMID: 17004726]
KB	IC₅₀	>100 μM Compound: Acyclovir	Tested for cytotoxic activity against human neoplastic cell line(KB cells). Tested for cytotoxic activity against human neoplastic cell line(KB cells).	[PMID: 2163453]
KB	IC₅₀	>100 μM Compound: Acyclovir	Tested in vitro for cytotoxicity against the human neoplastic cell line (KB cells). Tested in vitro for cytotoxicity against the human neoplastic cell line (KB cells).	[PMID: 2175356]
KB	IC₅₀	>100 μM Compound: Acyclovir	Cytotoxicity against human neoplastic cell line (KB) Cytotoxicity against human neoplastic cell line (KB)	[PMID: 2500527]
KB	IC₅₀	>100 μg/mL Compound: acyclovir	In vitro cytotoxicity against herpes simplex virus type-1 (HSV-1) HF strain in infected KB cells In vitro cytotoxicity against herpes simplex virus type-1 (HSV-1) HF strain in infected KB cells	[PMID: 2838633]
KB	IC₅₀	2.6 μg/mL Compound: acyclovir	Inhibitory activity against herpes simplex virus type-1 (HSV-1) replication in KB cells Inhibitory activity against herpes simplex virus type-1 (HSV-1) replication in KB cells	[PMID: 2838633]
KB	IC₅₀	>100 μM Compound: 1 (acyclovir)	Average percent inhibition of DNA, RNA, and protein synthesis determined in KB cells Average percent inhibition of DNA, RNA, and protein synthesis determined in KB cells	[PMID: 2840500]
KB	IC₅₀	>100 μM Compound: Acyclovir	Cytotoxicity was evaluated in Human neoplastic cell line (KB) Cytotoxicity was evaluated in Human neoplastic cell line (KB)	[PMID: 2913300]
KB	IC₅₀	>100 μM Compound: acyclovir	The inhibition of KB cell growth was determined The inhibition of KB cell growth was determined	[PMID: 8071942]
KB	IC₅₀	>100 μM Compound: Acyclovir (ACV)	Cytotoxicity (growth inhibition) against human epidermoid oral carcinoma KB cell line. Cytotoxicity (growth inhibition) against human epidermoid oral carcinoma KB cell line.	[PMID: 8784444]
MDCK	IC₅₀	0.1 μg/mL Compound: aciclovir	Antiviral activity against herpes simplex virus 1 infected in MDCK cells Antiviral activity against herpes simplex virus 1 infected in MDCK cells	[PMID: 16378363]
MDCK	IC₅₀	15.7 μg/mL Compound: acyclovir	Antiviral activity against influenza A virus H1N1 A/NWS/33 in human MDCK cells assessed as reduction of virus induced cytopathic effect Antiviral activity against influenza A virus H1N1 A/NWS/33 in human MDCK cells assessed as reduction of virus induced cytopathic effect	[PMID: 16724853]
MRC5	IC₅₀	0.25 μg/mL Compound: ACV	Tested for Antiherpetic activity against HSV-2 from 186 strain in MRC-5 cell lines. Tested for Antiherpetic activity against HSV-2 from 186 strain in MRC-5 cell lines.	[PMID: 10649983]
MRC5	IC₅₀	0.29 μg/mL Compound: ACV	Tested for Antiherpetic activity against HSV-1 from Tomioka strain in MRC-5 cell lines. Tested for Antiherpetic activity against HSV-1 from Tomioka strain in MRC-5 cell lines.	[PMID: 10649983]
MRC5	IC₅₀	1.3 μg/mL Compound: ACV	Tested for Antiherpetic activity against VZV from clinical isolates of MRC-5 cell lines.(average of six isolates) Tested for Antiherpetic activity against VZV from clinical isolates of MRC-5 cell lines.(average of six isolates)	[PMID: 10649983]
MRC5	EC₅₀	5 μM Compound: 1	Compound was tested for inhibition against varicella zoster virus(VZV) infected MRC5 cells Compound was tested for inhibition against varicella zoster virus(VZV) infected MRC5 cells	[PMID: 10762044]
MRC5	EC₅₀	50 μM Compound: 1	Compound was tested for inhibition against human cytomegalovirus (HCMV) in MRC-5 cells Compound was tested for inhibition against human cytomegalovirus (HCMV) in MRC-5 cells	[PMID: 10762044]
MRC5	IC₅₀	2.5 μM Compound: Acyclovir	Antiviral activity in plaque reduction assay was determined against herpes simplex virus type 2 (HSV-2) in MRC-5 cells. Antiviral activity in plaque reduction assay was determined against herpes simplex virus type 2 (HSV-2) in MRC-5 cells.	[PMID: 2153202]
MRC5	IC₅₀	20 μM Compound: Acyclovir	Antiviral activity in plaque reduction assay was determined against varicella zoster virus (VZV) in MRC-5 cells. Antiviral activity in plaque reduction assay was determined against varicella zoster virus (VZV) in MRC-5 cells.	[PMID: 2153202]
MRC5	IC₅₀	13 μM Compound: Acyclovir	Antiviral activity against Varicella zoster virus Ellen infected in human MRC5 cells assessed as inhibition of viral replication by viral reduction plaque assay Antiviral activity against Varicella zoster virus Ellen infected in human MRC5 cells assessed as inhibition of viral replication by viral reduction plaque assay	[PMID: 23219702]
MRC5	ED₅₀	1 μg/mL Compound: ACV	In vitro anti viral activity tested against VZV(KMcC) virus on MRC-5 cell monolayers; 1-2 In vitro anti viral activity tested against VZV(KMcC) virus on MRC-5 cell monolayers; 1-2	[PMID: 2989523]
MRC5	ED₅₀	20 μg/mL Compound: ACV	In vitro anti viral activity tested against HCMV(AD169) virus on MRC-5 cell monolayers; 20-25 In vitro anti viral activity tested against HCMV(AD169) virus on MRC-5 cell monolayers; 20-25	[PMID: 2989523]
MRC5	IC₅₀	>85 μM Compound: Acyclovir	Inhibitory activity against human cytomegalovirus (HCMV) strain AD169 in MRC-5 cells. Inhibitory activity against human cytomegalovirus (HCMV) strain AD169 in MRC-5 cells.	[PMID: 8576922]
MRC5	IC₅₀	46.8 μM Compound: Acyclovir	Inhibitory activity against varicella zoster virus (VZV) strain G31 in MRC-5 cells. Inhibitory activity against varicella zoster virus (VZV) strain G31 in MRC-5 cells.	[PMID: 8576922]
MRC5	CC₅₀	>=100 μM Compound: Acyclovir	The lowest concentration of compound producing overt cytotoxicity in virus-free MRC-5 cell cultures The lowest concentration of compound producing overt cytotoxicity in virus-free MRC-5 cell cultures	10.1016/0960-894X(95)00208-B
MRC5	EC₅₀	18 μM Compound: Acyclovir	Anti-herpes virus activity was evaluated against human cytomegalovirus (HCMV, strain AD-169) grown in MRC-5 cells Anti-herpes virus activity was evaluated against human cytomegalovirus (HCMV, strain AD-169) grown in MRC-5 cells	10.1016/0960-894X(95)00208-B
MT4	CC₅₀	>11.4 μg/mL Compound: Acyclovir	Cytotoxicity indicative of 50% survival concentration in HSV-2-uninfected MT-4 cells. Cytotoxicity indicative of 50% survival concentration in HSV-2-uninfected MT-4 cells.	[PMID: 12161143]
MT4	CC₅₀	>76.6 μg/mL Compound: Acyclovir	Cytotoxicity indicative of 50% survival concentration in HSV-1-uninfected MT-4 cells. Cytotoxicity indicative of 50% survival concentration in HSV-1-uninfected MT-4 cells.	[PMID: 12161143]
MT4	CC₅₀	>100 μM Compound: ACG	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	[PMID: 19482481]
MT4	CC₅₀	>250 μM Compound: 1, ACV	Cytotoxicity against human MT4 cells assessed as inhibition of cell proliferation Cytotoxicity against human MT4 cells assessed as inhibition of cell proliferation	[PMID: 19645484]
MT4	EC₅₀	>250 μM Compound: 1, ACV	Antiviral activity against HIV1 3B/Lai infected in human MT4 cells assessed as suppression of p24 production after 3 days Antiviral activity against HIV1 3B/Lai infected in human MT4 cells assessed as suppression of p24 production after 3 days	[PMID: 19645484]
MT4	IC₅₀	>250 μM Compound: 1, ACV	Cytotoxicity against human MT4 cells assessed as decrease in cell viability Cytotoxicity against human MT4 cells assessed as decrease in cell viability	[PMID: 19645484]
MT4	CC₅₀	>100 μM Compound: ACG	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	[PMID: 20359898]
MT4	CC₅₀	>250 μM Compound: 10, ACV	Cytotoxicity against human MT4 cells assessed as cell viability by propidium iodide staining-based cell counting analysis Cytotoxicity against human MT4 cells assessed as cell viability by propidium iodide staining-based cell counting analysis	[PMID: 24177359]
MT4	EC₅₀	>250 μM Compound: 10, ACV	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as p24 production after 3 days by microscopic analysis Antiviral activity against HIV1 3B infected in human MT4 cells assessed as p24 production after 3 days by microscopic analysis	[PMID: 24177359]
MT4	CC₅₀	>100 μM Compound: ACG	Cytotoxicity against mock-infected human MT4 cells after 96 hrs by MTT assay Cytotoxicity against mock-infected human MT4 cells after 96 hrs by MTT assay	[PMID: 25082514]
MT4	CC₅₀	>100 μM Compound: ACG	Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT assay	[PMID: 26443549]
MT4	IC₅₀	>100 μg/mL Compound: ACV	Tested for inhibitory effect on RNA virus cell growth in MT-4 cell line Tested for inhibitory effect on RNA virus cell growth in MT-4 cell line	[PMID: 8246242]
NC-37	CC₅₀	>100 μg/mL Compound: Acyclovir	Cytotoxic concentration required to inhibit NC-37 cells by 50% Cytotoxic concentration required to inhibit NC-37 cells by 50%	10.1016/S0960-894X(01)80146-3
NC-37	EC₅₀	0.17 μg/mL Compound: Acyclovir	Concentration required to reduce HSV-1 (KOS strain) induced cytopathogenicity in NC-37 cells Concentration required to reduce HSV-1 (KOS strain) induced cytopathogenicity in NC-37 cells	10.1016/S0960-894X(01)80146-3
Neoplastic cell line	IC₅₀	>100 μM Compound: acyclovir	Cytotoxic activity against KB cells. Cytotoxic activity against KB cells.	[PMID: 2163454]
P3HR-1	CC₅₀	392 μM Compound: ACV	Cytotoxic concentration for the inhibition of P3HR-1 cell growth Cytotoxic concentration for the inhibition of P3HR-1 cell growth	[PMID: 12408726]
P3HR-1	EC₅₀	6.75 μM Compound: ACV	Effective concentration for the inhibition of Epstein-Barr virus EBV-DNA synthesis in human lymphoblastoid P3HR-1 cells Effective concentration for the inhibition of Epstein-Barr virus EBV-DNA synthesis in human lymphoblastoid P3HR-1 cells	[PMID: 12408726]
Raji	ED₅₀	3.8 μg/mL Compound: Acyclovir	Tested for the inhibition of diffuse early antigen production assayed by immunofluorescent monoclonal antibody. Tested for the inhibition of diffuse early antigen production assayed by immunofluorescent monoclonal antibody.	[PMID: 2329551]
Raji	EC₅₀	2.9 μM Compound: acyclovir	Inhibitory concentration of the drug against the antigen production against P3HR-1 strain of epstein barr virus-2 (EBV) in Raji cells Inhibitory concentration of the drug against the antigen production against P3HR-1 strain of epstein barr virus-2 (EBV) in Raji cells	[PMID: 8394933]
RD	CC₅₀	>25 μM Compound: Acyclovir	Cytotoxicity against human RD cells Cytotoxicity against human RD cells	[PMID: 21356589]
Sf21	IC₅₀	>1000 μM Compound: Acyclovir	Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]
Sf21	IC₅₀	>1000 μM Compound: Acyclovir	Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]
Vero	CC₅₀	820 μg/mL Compound: ACV	Tested for cytotoxicity in vero cells, activity is expressed as CC50. Tested for cytotoxicity in vero cells, activity is expressed as CC50.	[PMID: 10649983]
Vero	CC₅₀	>5 μM Compound: 1	Compound was tested for cytotoxic activity uninfected vero cells Compound was tested for cytotoxic activity uninfected vero cells	[PMID: 10762044]
Vero	EC₅₀	3 μM Compound: 1	Compound was tested for inhibition against herpes simplex virus (HSV-2) infected vero cells Compound was tested for inhibition against herpes simplex virus (HSV-2) infected vero cells	[PMID: 10762044]
Vero	EC₅₀	6 μM Compound: acyclovir	Compound was evaluated for inhibition of HSV-1 induced plaques in vero cells (African green monkey kidney cells) Compound was evaluated for inhibition of HSV-1 induced plaques in vero cells (African green monkey kidney cells)	[PMID: 10987418]
Vero	IC₅₀	>50 μM Compound: Acyclovir	Concentration required to inhibit 50% of host cell replication in Vero cell used against HSV-1 and HSV-2 studies Concentration required to inhibit 50% of host cell replication in Vero cell used against HSV-1 and HSV-2 studies	[PMID: 10999490]
Vero	IC₅₀	2 μg/mL Compound: acyclovir	Antiviral activity against HSV1 infected in african green monkey Vero cells after 72 hrs by SRB assay Antiviral activity against HSV1 infected in african green monkey Vero cells after 72 hrs by SRB assay	[PMID: 11277765]
Vero	EC₅₀	117.6 μM Compound: Acyclovir	Inhibition of plaque formation in monolayers of HSV-1 KOSSB(TK-) Vero cells by 50% Inhibition of plaque formation in monolayers of HSV-1 KOSSB(TK-) Vero cells by 50%	[PMID: 11585457]
Vero	EC₅₀	2.2 μM Compound: Acyclovir	Inhibition of plaque formation in monolayers of HSV-1 KOS Vero cells by 50% Inhibition of plaque formation in monolayers of HSV-1 KOS Vero cells by 50%	[PMID: 11585457]
Vero	EC₅₀	2.6 μM Compound: Acyclovir	Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell in monolayers of VZV Ellen Vero cells by 50% Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell in monolayers of VZV Ellen Vero cells by 50%	[PMID: 11585457]
Vero	EC₅₀	4.4 μM Compound: Acyclovir	Inhibition of plaque formation in monolayers of HSV-1 E-377 Vero cells by 50% Inhibition of plaque formation in monolayers of HSV-1 E-377 Vero cells by 50%	[PMID: 11585457]
Vero	EC₅₀	6.2 μM Compound: Acyclovir	Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell monolayers of HSV-2 MS Vero cells by 50% Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell monolayers of HSV-2 MS Vero cells by 50%	[PMID: 11585457]
Vero	CC₅₀	>100 μg/mL Compound: 1b (Acyclovir)	Compound was evaluated for cytotoxicity against stationary Vero cells using MTT assay Compound was evaluated for cytotoxicity against stationary Vero cells using MTT assay	[PMID: 11677126]
Vero	EC₅₀	0.5 μg/mL Compound: 1b (Acyclovir)	Concentration required to inhibit plaque formation by HSV-1 strain KOS (TK+) in monolayers of vero cells Concentration required to inhibit plaque formation by HSV-1 strain KOS (TK+) in monolayers of vero cells	[PMID: 11677126]
Vero	EC₅₀	40 μg/mL Compound: 1b (Acyclovir)	Concentration required to inhibit plaque formation by HSV-1 strain KOSSB (TK-) in monolayers of vero cells Concentration required to inhibit plaque formation by HSV-1 strain KOSSB (TK-) in monolayers of vero cells	[PMID: 11677126]
Vero	IC₅₀	4.21 μg/mL Compound: acyclovir	Antiviral activity against Herpes simplex virus 2 infected in african green monkey Vero cells assessed inhibition of virus-induced effect after 48 hrs by MTT assay Antiviral activity against Herpes simplex virus 2 infected in african green monkey Vero cells assessed inhibition of virus-induced effect after 48 hrs by MTT assay	[PMID: 11678658]
Vero	CC₅₀	12.2 x 10⁴ ug/mL Compound: acyclovir	Cytotoxicity against african green monkey Vero cells by MTT assay Cytotoxicity against african green monkey Vero cells by MTT assay	[PMID: 11678658]
Vero	CC₅₀	>10 μg/mL Compound: ACV	Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay	[PMID: 12444692]
Vero	EC₅₀	0.8 μg/mL Compound: ACV	Antiviral activity against HSV1 F infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against HSV1 F infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	[PMID: 12444692]
Vero	EC₅₀	2.4 μg/mL Compound: ACV	Antiviral activity against HSV2 MS infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against HSV2 MS infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	[PMID: 12444692]
Vero	IC₅₀	1.2 μM Compound: acyclovir	In vitro antiherpesvirus activity against vero cells infected with HSV-2(G strain)[plaque reduction assay] In vitro antiherpesvirus activity against vero cells infected with HSV-2(G strain)[plaque reduction assay]	[PMID: 1323678]
Vero	CC₅₀	>400 μM Compound: Acyclovir (AVC)	In vitro cytotoxic concentration in vero cells. In vitro cytotoxic concentration in vero cells.	[PMID: 14584951]
Vero	ED₅₀	0.5 μM Compound: Acyclovir (AVC)	Inhibitory activity against HSV-1 in vero cells Inhibitory activity against HSV-1 in vero cells	[PMID: 14584951]
Vero	ED₅₀	2.5 μM Compound: Acyclovir (AVC)	Inhibitory activity against HSV-2 in vero cells Inhibitory activity against HSV-2 in vero cells	[PMID: 14584951]
Vero	ED₅₀	>1300 μM Compound: ACQ	Concentration of compound required to reduce by 50% the number of african swine fever virus (ASFV) plaques in vero cells Concentration of compound required to reduce by 50% the number of african swine fever virus (ASFV) plaques in vero cells	[PMID: 1548681]
Vero	ED₅₀	0.04 μM Compound: ACQ	Concentration of compound required to reduce by 50% the number of herpes simplex virus (HSV-1) plaques in vero cells Concentration of compound required to reduce by 50% the number of herpes simplex virus (HSV-1) plaques in vero cells	[PMID: 1548681]
Vero	CC₅₀	>200 μM Compound: Acyclovir	Cytotoxic concentration required to inhibit herpes simplex virus 1 infected vero cells Cytotoxic concentration required to inhibit herpes simplex virus 1 infected vero cells	[PMID: 15634003]
Vero	CC₅₀	>200 μM Compound: Acyclovir	Cytotoxic concentration required to inhibit herpes simplex virus 2 infected vero cells Cytotoxic concentration required to inhibit herpes simplex virus 2 infected vero cells	[PMID: 15634003]
Vero	EC₅₀	13.5 μM Compound: Acyclovir	Effective concentration required to inhibit herpes simplex virus 1 in vero cells in plaque reduction assay Effective concentration required to inhibit herpes simplex virus 1 in vero cells in plaque reduction assay	[PMID: 15634003]
Vero	EC₅₀	32.3 μM Compound: Acyclovir	Effective concentration required to inhibit herpes simplex virus 2 in vero cells in plaque reduction assay Effective concentration required to inhibit herpes simplex virus 2 in vero cells in plaque reduction assay	[PMID: 15634003]
Vero	CC₅₀	>100 μM Compound: acyclovir	Toxicity on uninfected African green monkey kidney cells determined in microscopic evaluation and quantitative neutral red dye uptake assay Toxicity on uninfected African green monkey kidney cells determined in microscopic evaluation and quantitative neutral red dye uptake assay	[PMID: 16134946]
Vero	IC₅₀	>10 μM Compound: acyclovir	Antiviral activity against herpes simplex virus type 1 KOS (AraAr13) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO Antiviral activity against herpes simplex virus type 1 KOS (AraAr13) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO	[PMID: 16134946]
Vero	IC₅₀	>10 μM Compound: acyclovir	Antiviral activity against herpes simplex virus type 1 KOS (PAAr5) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO Antiviral activity against herpes simplex virus type 1 KOS (PAAr5) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO	[PMID: 16134946]
Vero	IC₅₀	>10 μM Compound: acyclovir	Antiviral activity against herpes simplex virus type 1 KOS (PFAr2) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO Antiviral activity against herpes simplex virus type 1 KOS (PFAr2) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO	[PMID: 16134946]
Vero	IC₅₀	>10 μM Compound: acyclovir	Antiviral activity against herpes simplex virus type 1 Patton (BWr) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO Antiviral activity against herpes simplex virus type 1 Patton (BWr) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO	[PMID: 16134946]
Vero	IC₅₀	2.1 μM Compound: acyclovir	Antiviral activity against herpes simplex virus type 1 (KOS strain) grown on human foreskin fibroblast cells determined by vedduction in plaque formation upon incubation at 37 degrees C with the compound dissolved in DMSO until plaque were formed [nd = no Antiviral activity against herpes simplex virus type 1 (KOS strain) grown on human foreskin fibroblast cells determined by vedduction in plaque formation upon incubation at 37 degrees C with the compound dissolved in DMSO until plaque were formed [nd = no	[PMID: 16134946]
Vero	IC₅₀	2.4 μM Compound: acyclovir	Antiviral activity against herpes simplex virus type 2 (WT) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO Antiviral activity against herpes simplex virus type 2 (WT) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO	[PMID: 16134946]
Vero	IC₅₀	2.8 μM Compound: acyclovir	Antiviral activity against herpes simplex virus type 2 (V826A) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO Antiviral activity against herpes simplex virus type 2 (V826A) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO	[PMID: 16134946]
Vero	IC₅₀	3.5 μM Compound: acyclovir	Antiviral activity against herpes simplex virus type 1 KOS (WT) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO Antiviral activity against herpes simplex virus type 1 KOS (WT) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO	[PMID: 16134946]
Vero	IC₅₀	4.4 μM Compound: acyclovir	Antiviral activity against herpes simplex virus type 1 KOS (V823A) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO Antiviral activity against herpes simplex virus type 1 KOS (V823A) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO	[PMID: 16134946]
Vero	IC₅₀	5.4 μM Compound: acyclovir	Antiviral activity against herpes simplex virus type 1 Patton (WT) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO Antiviral activity against herpes simplex virus type 1 Patton (WT) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO	[PMID: 16134946]
Vero	CC₅₀	960 μM Compound: ACV	Cytotoxicity against Vero cells by MTT assay Cytotoxicity against Vero cells by MTT assay	[PMID: 16321530]
Vero	EC₅₀	1.09 μM Compound: ACV	Antiviral activity against HSV1 in vero cells Antiviral activity against HSV1 in vero cells	[PMID: 16321530]
Vero	CC₅₀	>500 μg/mL Compound: acyclovir	Cytotoxicity against african green monkey Vero cells after 3 days by MTT reduction assay Cytotoxicity against african green monkey Vero cells after 3 days by MTT reduction assay	[PMID: 16724853]
Vero	IC₅₀	0.25 μg/mL Compound: acyclovir	Antiviral activity against HSV1 15577 in african green monkey Vero cells assessed as reduction of virus induced cytopathic effect Antiviral activity against HSV1 15577 in african green monkey Vero cells assessed as reduction of virus induced cytopathic effect	[PMID: 16724853]
Vero	CC₅₀	>200 μM Compound: ACV	Cytotoxicity against Vero cells Cytotoxicity against Vero cells	[PMID: 17368024]
Vero	IC₅₀	0.39 μM Compound: ACV	Antiviral activity against HSV1 SC16 in Vero cells by capture hybrid method Antiviral activity against HSV1 SC16 in Vero cells by capture hybrid method	[PMID: 17368024]
Vero	IC₅₀	2100 nM Compound: acyclovir	Antiviral activity against HSV1 KOS in Vero cells by plaque reduction assay Antiviral activity against HSV1 KOS in Vero cells by plaque reduction assay	[PMID: 17434304]
Vero	CC₅₀	>890 μM Compound: ACV	Cytotoxicity against african green monkey Vero cells after 2 days Cytotoxicity against african green monkey Vero cells after 2 days	[PMID: 17438061]
Vero	EC₅₀	1.4 μM Compound: ACV	Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	[PMID: 17438061]
Vero	EC₅₀	112 μM Compound: ACV	Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	[PMID: 17438061]
Vero	EC₅₀	118 μM Compound: ACV	Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	[PMID: 17438061]
Vero	EC₅₀	47.5 μM Compound: ACV	Antiviral activity against Herpes B virus E90-136 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs Antiviral activity against Herpes B virus E90-136 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	[PMID: 17438061]
Vero	CC₅₀	126 μM Compound: acyclovir	Cytotoxicity against african green monkey Vero cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 17937990]
Vero	CC₅₀	>100 μM Compound: Acyclovir	Cytotoxicity against african green monkey Vero cells after 69 hrs by Alamar blue assay Cytotoxicity against african green monkey Vero cells after 69 hrs by Alamar blue assay	[PMID: 17981031]
Vero	EC₅₀	6 μM Compound: Acyclovir	Antiviral activity against HSV1 KOS in african green monkey Vero cells by plaque reduction assay Antiviral activity against HSV1 KOS in african green monkey Vero cells by plaque reduction assay	[PMID: 17981031]
Vero	CC₅₀	>200 μM Compound: ACV, acyclovir	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 18086523]
Vero	IC₅₀	0.39 μM Compound: ACV, acyclovir	Antiviral activity against HSV1 SC16 in african green monkey Vero cells Antiviral activity against HSV1 SC16 in african green monkey Vero cells	[PMID: 18086523]
Vero	EC₅₀	>100 μM Compound: 1, ACV	Antiviral activity against acyclovir-resistant HSV2 ACR in african green monkey Vero cells assessed as inhibition of virus plaque formation Antiviral activity against acyclovir-resistant HSV2 ACR in african green monkey Vero cells assessed as inhibition of virus plaque formation	[PMID: 18614365]
Vero	EC₅₀	6 μM Compound: 1, ACV	Antiviral activity against acyclovir-sensitive HSV2 HG32 in african green monkey Vero cells assessed as inhibition of virus plaque formation Antiviral activity against acyclovir-sensitive HSV2 HG32 in african green monkey Vero cells assessed as inhibition of virus plaque formation	[PMID: 18614365]
Vero	IC₅₀	0.32 μM Compound: ACV	Antiviral activity against acyclovir-sensitive HSV1 L177 isolate replication in african green monkey Vero cells by plaque reduction assay Antiviral activity against acyclovir-sensitive HSV1 L177 isolate replication in african green monkey Vero cells by plaque reduction assay	[PMID: 19010684]
Vero	IC₅₀	0.58 μM Compound: ACV	Antiviral activity against acyclovir-sensitive HSV1 K161 isolate replication in african green monkey Vero cells by plaque reduction assay Antiviral activity against acyclovir-sensitive HSV1 K161 isolate replication in african green monkey Vero cells by plaque reduction assay	[PMID: 19010684]
Vero	IC₅₀	3.04 μM Compound: ACV	Antiviral activity against acyclovir-sensitive HSV1 KOS isolate replication in african green monkey Vero cells by plaque reduction assay Antiviral activity against acyclovir-sensitive HSV1 KOS isolate replication in african green monkey Vero cells by plaque reduction assay	[PMID: 19010684]
Vero	IC₅₀	31.2 μM Compound: ACV	Antiviral activity against acyclovir-resistant HSV1 KOS-M isolate replication in african green monkey Vero cells by plaque reduction assay Antiviral activity against acyclovir-resistant HSV1 KOS-M isolate replication in african green monkey Vero cells by plaque reduction assay	[PMID: 19010684]
Vero	IC₅₀	75.07 μM Compound: ACV	Antiviral activity against acyclovir-resistant HSV1 K143 isolate replication in african green monkey Vero cells by plaque reduction assay Antiviral activity against acyclovir-resistant HSV1 K143 isolate replication in african green monkey Vero cells by plaque reduction assay	[PMID: 19010684]
Vero	IC₅₀	9.51 μM Compound: ACV	Antiviral activity against acyclovir-resistant HSV1 L182 isolate replication in african green monkey Vero cells by plaque reduction assay Antiviral activity against acyclovir-resistant HSV1 L182 isolate replication in african green monkey Vero cells by plaque reduction assay	[PMID: 19010684]
Vero	IC₅₀	0.0043 mM Compound: acyclovir	Antiviral activity against HSV1 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days Antiviral activity against HSV1 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days	[PMID: 19422205]
Vero	CC₅₀	>100 μM Compound: ACG	Cytotoxicity against african green monkey Vero 76 cells by crystal violet staining Cytotoxicity against african green monkey Vero 76 cells by crystal violet staining	[PMID: 19482481]
Vero	CC₅₀	>200 μM Compound: ACV, Zovirax	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 19700316]
Vero	IC₅₀	0.39 μM Compound: ACV, Zovirax	Antiviral activity against HSV1 SC16 infected in african green monkey Vero cells by hybrid capture method Antiviral activity against HSV1 SC16 infected in african green monkey Vero cells by hybrid capture method	[PMID: 19700316]
Vero	EC₅₀	19.3 μM Compound: ACV	Antiviral activity against HSV1 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against HSV1 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: ACV	Antiviral activity against HSV2 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against HSV2 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: ACV	Antiviral activity against Macacine herpesvirus 1 isolate A1 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate A1 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: ACV	Antiviral activity against Macacine herpesvirus 1 isolate A2 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate A2 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: ACV	Antiviral activity against Macacine herpesvirus 1 isolate A3 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate A3 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: ACV	Antiviral activity against Macacine herpesvirus 1 isolate A4 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate A4 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: ACV	Antiviral activity against Macacine herpesvirus 1 isolate A5 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate A5 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: ACV	Antiviral activity against Macacine herpesvirus 1 isolate A6 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate A6 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: ACV	Antiviral activity against Macacine herpesvirus 1 isolate E2490 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate E2490 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: ACV	Antiviral activity against Macacine herpesvirus 1 isolate MC1 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MC1 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: ACV	Antiviral activity against Macacine herpesvirus 1 isolate MC2 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MC2 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: ACV	Antiviral activity against Macacine herpesvirus 1 isolate MJ1 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MJ1 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: ACV	Antiviral activity against Macacine herpesvirus 1 isolate MJ2 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MJ2 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: ACV	Antiviral activity against Macacine herpesvirus 1 isolate MJ3 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MJ3 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: ACV	Antiviral activity against Macacine herpesvirus 1 isolate MP1 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MP1 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: ACV	Antiviral activity against Macacine herpesvirus 1 isolate MR1 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR1 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: ACV	Antiviral activity against Macacine herpesvirus 1 isolate MR10 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR10 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: ACV	Antiviral activity against Macacine herpesvirus 1 isolate MR11 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR11 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: ACV	Antiviral activity against Macacine herpesvirus 1 isolate MR2 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR2 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: ACV	Antiviral activity against Macacine herpesvirus 1 isolate MR3 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR3 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: ACV	Antiviral activity against Macacine herpesvirus 1 isolate MR4 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR4 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: ACV	Antiviral activity against Macacine herpesvirus 1 isolate MR5 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR5 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: ACV	Antiviral activity against Macacine herpesvirus 1 isolate MR6 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR6 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: ACV	Antiviral activity against Macacine herpesvirus 1 isolate MR7 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR7 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: ACV	Antiviral activity against Macacine herpesvirus 1 isolate MR8 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR8 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: ACV	Antiviral activity against Macacine herpesvirus 1 isolate MR9 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR9 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	IC₅₀	0.0043 mM Compound: aciclovir	Antiviral activity against HSV1 infected african green monkey Vero cells assessed as reduction of plaque formation after 3 days by using crystal violet stain Antiviral activity against HSV1 infected african green monkey Vero cells assessed as reduction of plaque formation after 3 days by using crystal violet stain	[PMID: 20092288]
Vero	CC₅₀	>100 μM Compound: ACG	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 20359898]
Vero	EC₅₀	>100 μM Compound: ACG	Antiviral activity against Human coxsackievirus B2 Ohio-1 infected in african green monkey Vero cells after 3 days by plaque reduction assay Antiviral activity against Human coxsackievirus B2 Ohio-1 infected in african green monkey Vero cells after 3 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	>100 μM Compound: ACG	Antiviral activity against Polio virus type1 Sabin strain Chat infected in african green monkey Vero cells after 2 days by plaque reduction assay Antiviral activity against Polio virus type1 Sabin strain Chat infected in african green monkey Vero cells after 2 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	>100 μM Compound: ACG	Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	>100 μM Compound: ACG	Antiviral activity against Vaccinia virus Elstree-Lister infected in african green monkey Vero cells after 3 days by plaque reduction assay Antiviral activity against Vaccinia virus Elstree-Lister infected in african green monkey Vero cells after 3 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	3 μM Compound: ACG	Antiviral activity against HSV1 KOS infected in african green monkey Vero cells after 3 days by plaque reduction assay Antiviral activity against HSV1 KOS infected in african green monkey Vero cells after 3 days by plaque reduction assay	[PMID: 20359898]
Vero	IC₅₀	2.1 μM Compound: Acyclovir	Antiviral activity against HSV1 KOS infected in african green monkey Vero cells assessed as reduction in plaque formation Antiviral activity against HSV1 KOS infected in african green monkey Vero cells assessed as reduction in plaque formation	[PMID: 20403696]
Vero	EC₅₀	>50 μM Compound: ACV	Antiviral activity against Herpes simplex virus 1 isolate 1 harboring C6G N23S K36E L42P G240E A265T and A207P mutations in thymidine kinase and S33G, A330R, N425T, V905M mutations in DNA polymerase infected in african green monkey Vero cells by plaque re Antiviral activity against Herpes simplex virus 1 isolate 1 harboring C6G N23S K36E L42P G240E A265T and A207P mutations in thymidine kinase and S33G, A330R, N425T, V905M mutations in DNA polymerase infected in african green monkey Vero cells by plaque re	[PMID: 20733037]
Vero	EC₅₀	>50 μM Compound: ACV	Antiviral activity against Herpes simplex virus 1 isolate 11 harboring N23S, K36E, G251C, A265T, P268T, R176W mutations in thymidine kinase and S33G, A330R, P1124H, T1208A, S724N, V117L, L267M mutations in DNA polymerase infected in african green monkey V Antiviral activity against Herpes simplex virus 1 isolate 11 harboring N23S, K36E, G251C, A265T, P268T, R176W mutations in thymidine kinase and S33G, A330R, P1124H, T1208A, S724N, V117L, L267M mutations in DNA polymerase infected in african green monkey V	[PMID: 20733037]
Vero	EC₅₀	>50 μM Compound: ACV	Antiviral activity against Herpes simplex virus 1 isolate 9 harboring N23S, K36E, R89Q, +1G 437-438 = Stop 228 mutations in thymidine kinase and S33G, A330R, V905M, A1203T, T1208A mutations in DNA polymerase infected in african green monkey Vero cells by Antiviral activity against Herpes simplex virus 1 isolate 9 harboring N23S, K36E, R89Q, +1G 437-438 = Stop 228 mutations in thymidine kinase and S33G, A330R, V905M, A1203T, T1208A mutations in DNA polymerase infected in african green monkey Vero cells by	[PMID: 20733037]
Vero	EC₅₀	>50 μM Compound: ACV	Antiviral activity against Herpes simplex virus 2 isolate 16 harboring D137Stop mutations in thymidine kinase and A9T, P15S, L60P mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Herpes simplex virus 2 isolate 16 harboring D137Stop mutations in thymidine kinase and A9T, P15S, L60P mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay	[PMID: 20733037]
Vero	EC₅₀	>50 μM Compound: ACV	Antiviral activity against Herpes simplex virus 2 isolate 17 harboring G39E, N78D Q222Stop mutations in thymidine kinase and A9T, P15S, L60P, T801P mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Herpes simplex virus 2 isolate 17 harboring G39E, N78D Q222Stop mutations in thymidine kinase and A9T, P15S, L60P, T801P mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay	[PMID: 20733037]
Vero	EC₅₀	>50 μM Compound: ACV	Antiviral activity against Herpes simplex virus 2 isolate 19 harboring G39E, +2G 439-440 = Stop 184 mutations in thymidine kinase and A9T, P15S, L60P, del, DGDE683-686 mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduc Antiviral activity against Herpes simplex virus 2 isolate 19 harboring G39E, +2G 439-440 = Stop 184 mutations in thymidine kinase and A9T, P15S, L60P, del, DGDE683-686 mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduc	[PMID: 20733037]
Vero	EC₅₀	>50 μM Compound: ACV	Antiviral activity against Herpes simplex virus 2 isolate 20 harboring G39E, -1C 467 = Stop 183 mutations in thymidine kinase and A9T, P15S, L60P, E139K, T801P mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction ass Antiviral activity against Herpes simplex virus 2 isolate 20 harboring G39E, -1C 467 = Stop 183 mutations in thymidine kinase and A9T, P15S, L60P, E139K, T801P mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction ass	[PMID: 20733037]
Vero	EC₅₀	>50 μM Compound: ACV	Antiviral activity against Herpes simplex virus 2 isolate 21 harboring G39E, N78D, L140F, -1C 452 = Stop 183 mutations in thymidine kinase and P15S, L60P, E678G mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction as Antiviral activity against Herpes simplex virus 2 isolate 21 harboring G39E, N78D, L140F, -1C 452 = Stop 183 mutations in thymidine kinase and P15S, L60P, E678G mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction as	[PMID: 20733037]
Vero	EC₅₀	>50 μM Compound: ACV	Antiviral activity against Herpes simplex virus 2 isolate 22 harboring G39E, N78D, L140F, +1G 439-440 = Stop 229 mutations in thymidine kinase and A9T, P15S, L60P, E678G, Y823C mutations in DNA polymerase infected in african green monkey Vero cells by pla Antiviral activity against Herpes simplex virus 2 isolate 22 harboring G39E, N78D, L140F, +1G 439-440 = Stop 229 mutations in thymidine kinase and A9T, P15S, L60P, E678G, Y823C mutations in DNA polymerase infected in african green monkey Vero cells by pla	[PMID: 20733037]
Vero	EC₅₀	>50 μM Compound: ACV	Antiviral activity against Herpes simplex virus 2 isolate 23 harboring G39E, N78D, L140F, +1G 439-440 = Stop 229 mutations in thymidine kinase and A9T, P15S, L60P, I291V mutations in DNA polymerase infected in african green monkey Vero cells by plaque red Antiviral activity against Herpes simplex virus 2 isolate 23 harboring G39E, N78D, L140F, +1G 439-440 = Stop 229 mutations in thymidine kinase and A9T, P15S, L60P, I291V mutations in DNA polymerase infected in african green monkey Vero cells by plaque red	[PMID: 20733037]
Vero	EC₅₀	>50 μM Compound: ACV	Antiviral activity against Herpes simplex virus 2 isolate 24 harboring G39E, -1G 440 = Stop 229 mutations in thymidine kinase and A9T, P15S, L60P, E139K, H837R mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction ass Antiviral activity against Herpes simplex virus 2 isolate 24 harboring G39E, -1G 440 = Stop 229 mutations in thymidine kinase and A9T, P15S, L60P, E139K, H837R mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction ass	[PMID: 20733037]
Vero	EC₅₀	10 μM Compound: ACV	Antiviral activity against Herpes simplex virus 1 isolate 8 harboring N23S, K36E, R89Q, +1G 437-438 = Stop 228 mutations in thymidine kinase and A330R, P875S, V905M, P1124H, T1208A mutations in DNA polymerase infected in african green monkey Vero cells by Antiviral activity against Herpes simplex virus 1 isolate 8 harboring N23S, K36E, R89Q, +1G 437-438 = Stop 228 mutations in thymidine kinase and A330R, P875S, V905M, P1124H, T1208A mutations in DNA polymerase infected in african green monkey Vero cells by	[PMID: 20733037]
Vero	EC₅₀	11 μM Compound: ACV	Antiviral activity against Herpes simplex virus 1 isolate 2 harboring C6G, N23S, K36E, R41H, A192V, A265T, L170P mutations in thymidine kinase and S33G, A330R, N425T, V905M, T1208A mutations in DNA polymerase infected in african green monkey Vero cells by Antiviral activity against Herpes simplex virus 1 isolate 2 harboring C6G, N23S, K36E, R41H, A192V, A265T, L170P mutations in thymidine kinase and S33G, A330R, N425T, V905M, T1208A mutations in DNA polymerase infected in african green monkey Vero cells by	[PMID: 20733037]
Vero	EC₅₀	11 μM Compound: ACV	Antiviral activity against Herpes simplex virus 2 isolate 15 harboring R221H mutations in thymidine kinase and A9T, P15S, L60P mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Herpes simplex virus 2 isolate 15 harboring R221H mutations in thymidine kinase and A9T, P15S, L60P mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay	[PMID: 20733037]
Vero	EC₅₀	16 μM Compound: ACV	Antiviral activity against Herpes simplex virus 1 isolate 4 harboring N23S, K36E -1C 553 = frameshift mutations in thymidine kinase and S33G, A330R, A899V, L1188F mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction Antiviral activity against Herpes simplex virus 1 isolate 4 harboring N23S, K36E -1C 553 = frameshift mutations in thymidine kinase and S33G, A330R, A899V, L1188F mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction	[PMID: 20733037]
Vero	EC₅₀	16 μM Compound: ACV	Antiviral activity against Herpes simplex virus 1 isolate 5 harboring N23S, K36E, A192V, G251C, A265T, V267L, P268T, -1G 856 = frameshift mutations in thymidine kinase and A330R, V905M, T1208A, H98Y mutations in DNA polymerase infected in african green mo Antiviral activity against Herpes simplex virus 1 isolate 5 harboring N23S, K36E, A192V, G251C, A265T, V267L, P268T, -1G 856 = frameshift mutations in thymidine kinase and A330R, V905M, T1208A, H98Y mutations in DNA polymerase infected in african green mo	[PMID: 20733037]
Vero	EC₅₀	18 μM Compound: ACV	Antiviral activity against Herpes simplex virus 2 isolate 18 harboring A27T, G39E, N78D, -1C 556 = Stop 263, S29A mutations in thymidine kinase and A9T, P15S, L60P, E678G, del, DD676-677 mutations in DNA polymerase infected in african green monkey Vero ce Antiviral activity against Herpes simplex virus 2 isolate 18 harboring A27T, G39E, N78D, -1C 556 = Stop 263, S29A mutations in thymidine kinase and A9T, P15S, L60P, E678G, del, DD676-677 mutations in DNA polymerase infected in african green monkey Vero ce	[PMID: 20733037]
Vero	EC₅₀	22 μM Compound: ACV	Antiviral activity against Herpes simplex virus 1 isolate 10 harboring N23S, K36E, R89Q, A265T C336Y mutations in thymidine kinase and S33G, A330R, V905M mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Herpes simplex virus 1 isolate 10 harboring N23S, K36E, R89Q, A265T C336Y mutations in thymidine kinase and S33G, A330R, V905M mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay	[PMID: 20733037]
Vero	EC₅₀	24 μM Compound: ACV	Antiviral activity against Herpes simplex virus 2 isolate 14 harboring G39E, N78D, M70R mutations in thymidine kinase and A724V mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Herpes simplex virus 2 isolate 14 harboring G39E, N78D, M70R mutations in thymidine kinase and A724V mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay	[PMID: 20733037]
Vero	EC₅₀	26 μM Compound: ACV	Antiviral activity against Herpes simplex virus 1 isolate 6 harboring N23S, K36E, R89Q, +1G 437-438 = Stop 225 mutations in thymidine kinase and S33G, A330R, A646T, S1123L, P1124H, T1208A, R1229I mutations in DNA polymerase infected in african green monke Antiviral activity against Herpes simplex virus 1 isolate 6 harboring N23S, K36E, R89Q, +1G 437-438 = Stop 225 mutations in thymidine kinase and S33G, A330R, A646T, S1123L, P1124H, T1208A, R1229I mutations in DNA polymerase infected in african green monke	[PMID: 20733037]
Vero	EC₅₀	31 μM Compound: ACV	Antiviral activity against Herpes simplex virus 1 isolate 7 harboring N23S, K36E, R89Q, +1C 464-465 = Stop 228 mutations in thymidine kinase and S33G, A330R, P1124H, T1208A, A870G mutations in DNA polymerase infected in african green monkey Vero cells by Antiviral activity against Herpes simplex virus 1 isolate 7 harboring N23S, K36E, R89Q, +1C 464-465 = Stop 228 mutations in thymidine kinase and S33G, A330R, P1124H, T1208A, A870G mutations in DNA polymerase infected in african green monkey Vero cells by	[PMID: 20733037]
Vero	EC₅₀	33 μM Compound: ACV	Antiviral activity against Herpes simplex virus 2 isolate 13 harboring, M183I mutations in thymidine kinase and A9T, P15S, R41H, L60P, E139K, A232T mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Herpes simplex virus 2 isolate 13 harboring, M183I mutations in thymidine kinase and A9T, P15S, R41H, L60P, E139K, A232T mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay	[PMID: 20733037]
Vero	EC₅₀	35 μM Compound: ACV	Antiviral activity against Herpes simplex virus 1 isolate 3 harboring N23S, K36E, R89Q, A265T, Y53D mutations in thymidine kinase and S33G, A330R, V905M, E1005K mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction as Antiviral activity against Herpes simplex virus 1 isolate 3 harboring N23S, K36E, R89Q, A265T, Y53D mutations in thymidine kinase and S33G, A330R, V905M, E1005K mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction as	[PMID: 20733037]
Vero	EC₅₀	42 μM Compound: ACV	Antiviral activity against Herpes simplex virus 2 isolate 25 harboring I101S mutations in thymidine kinase and D785N, V544A mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Herpes simplex virus 2 isolate 25 harboring I101S mutations in thymidine kinase and D785N, V544A mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay	[PMID: 20733037]
Vero	EC₅₀	43 μM Compound: ACV	Antiviral activity against Herpes simplex virus 2 isolate 12 harboring G39E, N78D, L140F, S66P, A72S mutations in thymidine kinase and A9T, P15S, L60P mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Herpes simplex virus 2 isolate 12 harboring G39E, N78D, L140F, S66P, A72S mutations in thymidine kinase and A9T, P15S, L60P mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay	[PMID: 20733037]
Vero	CC₅₀	>200 μM Compound: ACV	Cytotoxicity against african green monkey Vero cells by MTT assay Cytotoxicity against african green monkey Vero cells by MTT assay	[PMID: 21334891]
Vero	EC₅₀	1.16 μM Compound: ACV	Antiviral activity against HSV1 infected in african green monkey Vero cells assessed as inhibition of viral replication by plaque reduction assay Antiviral activity against HSV1 infected in african green monkey Vero cells assessed as inhibition of viral replication by plaque reduction assay	[PMID: 21334891]
Vero	EC₅₀	1.72 μM Compound: ACV	Antiviral activity against HSV2 infected in african green monkey Vero cells assessed as inhibition of viral replication by plaque reduction assay Antiviral activity against HSV2 infected in african green monkey Vero cells assessed as inhibition of viral replication by plaque reduction assay	[PMID: 21334891]
Vero	CC₅₀	860 μM Compound: 1, ACV	Cytotoxicity against african green monkey Vero cells after 72 hrs by XTT assay Cytotoxicity against african green monkey Vero cells after 72 hrs by XTT assay	[PMID: 21376603]
Vero	IC₅₀	0.99 μM Compound: 1, ACV	Antiviral activity against 5 MOI Herpes simplex viruses 1 infected in vero cells after 24 hrs by viral plaque number reduction assay Antiviral activity against 5 MOI Herpes simplex viruses 1 infected in vero cells after 24 hrs by viral plaque number reduction assay	[PMID: 21376603]
Vero	IC₅₀	6.7 μM Compound: Acyclovir	Antiviral activity in plaque reduction assay was determined against herpes simplex virus type 1 (HSV-1) in Vero cells. Antiviral activity in plaque reduction assay was determined against herpes simplex virus type 1 (HSV-1) in Vero cells.	[PMID: 2153202]
Vero	CC₅₀	>100 μM Compound: ACG	Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by crystal violet staining Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by crystal violet staining	[PMID: 22047799]
Vero	EC₅₀	3 μM Compound: ACG	Antiviral activity against Human herpesvirus 1 strain KOS infected in african green monkey Vero 76 cells assessed as reduction of virus-induced plaque formation after 3 days using crystal violet staining Antiviral activity against Human herpesvirus 1 strain KOS infected in african green monkey Vero 76 cells assessed as reduction of virus-induced plaque formation after 3 days using crystal violet staining	[PMID: 22047799]
Vero	CC₅₀	>100 μM Compound: Acycloguanosine	Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay	[PMID: 22513121]
Vero	CC₅₀	>200 μM Compound: ACV	Cytotoxicity against african green monkey Vero cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against african green monkey Vero cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 22704890]
Vero	EC₅₀	1.2 μM Compound: ACV	Antiviral activity against HSV1 strain F ATCC VR733 infected in african green monkey Vero cells assessed as inhibition of cytopathic effect after 48 hrs by plaque reduction assay Antiviral activity against HSV1 strain F ATCC VR733 infected in african green monkey Vero cells assessed as inhibition of cytopathic effect after 48 hrs by plaque reduction assay	[PMID: 22704890]
Vero	EC₅₀	1.87 μM Compound: ACV	Antiviral activity against HSV2 strain 333 infected in african green monkey Vero cells assessed as inhibition of cytopathic effect after 48 hrs by plaque reduction assay Antiviral activity against HSV2 strain 333 infected in african green monkey Vero cells assessed as inhibition of cytopathic effect after 48 hrs by plaque reduction assay	[PMID: 22704890]
Vero	CC₅₀	130 μg/mL Compound: ACV	Cytotoxicity against african green monkey Vero cells after 2 days by MTT assay Cytotoxicity against african green monkey Vero cells after 2 days by MTT assay	[PMID: 22921079]
Vero	EC₅₀	1.6 μg/mL Compound: ACV	Antiviral activity against HSV-1F ATCC 733 infected in african green monkey Vero cells after 2 to 3 days by plaque reduction assay Antiviral activity against HSV-1F ATCC 733 infected in african green monkey Vero cells after 2 to 3 days by plaque reduction assay	[PMID: 22921079]
Vero	EC₅₀	1.8 μg/mL Compound: ACV	Antiviral activity against HSV-2G ATCC 734 infected in african green monkey Vero cells after 2 to 3 days by plaque reduction assay Antiviral activity against HSV-2G ATCC 734 infected in african green monkey Vero cells after 2 to 3 days by plaque reduction assay	[PMID: 22921079]
Vero	EC₅₀	2.1 μg/mL Compound: ACV	Antiviral activity against HSV-1F ATCC 733 infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathic effect after 3 days by MTT assay Antiviral activity against HSV-1F ATCC 733 infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathic effect after 3 days by MTT assay	[PMID: 22921079]
Vero	EC₅₀	0.5 μM Compound: acyclovir	Antiviral activity against Herpes simplex virus (type 1 / strain F) infected in Vero cells assessed as reduction of number of viral plaques after 2 days Antiviral activity against Herpes simplex virus (type 1 / strain F) infected in Vero cells assessed as reduction of number of viral plaques after 2 days	[PMID: 22944333]
Vero	EC₅₀	1.7 μM Compound: 1, Acyclovir, ACV	Antiviral activity against HSV1 L2 infected in Vero E6 cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs Antiviral activity against HSV1 L2 infected in Vero E6 cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs	[PMID: 22954898]
Vero	EC₅₀	530 μM Compound: 1, Acyclovir, ACV	Antiviral activity against acyclovir-resistant HSV1 L2 infected in Vero E6 cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs Antiviral activity against acyclovir-resistant HSV1 L2 infected in Vero E6 cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs	[PMID: 22954898]
Vero	CC₅₀	>2000 μM Compound: 1, Acyclovir, ACV	Cytotoxicity against african green monkey Vero E6 cells after 72 hrs by trypan blue staining Cytotoxicity against african green monkey Vero E6 cells after 72 hrs by trypan blue staining	[PMID: 22954898]
Vero	CC₅₀	>200 μM Compound: Acyclovir	Cytotoxicity against african green monkey Vero cells after 3 days by neutral red dye method Cytotoxicity against african green monkey Vero cells after 3 days by neutral red dye method	[PMID: 23141915]
Vero	EC₅₀	0.76 μM Compound: Acyclovir	Antiviral activity against Herpes simplex virus type 1 infected in Vero cells at 0.001 ID50/cells assessed as protection against virus-induced cytopathic effect after 3 days by neutral red dye method Antiviral activity against Herpes simplex virus type 1 infected in Vero cells at 0.001 ID50/cells assessed as protection against virus-induced cytopathic effect after 3 days by neutral red dye method	[PMID: 23141915]
Vero	EC₅₀	22 μM Compound: Acyclovir	Antiviral activity against Herpes simplex virus type 1 infected in Vero cells at 0.01 ID50/cells assessed as protection against virus-induced cytopathic effect after 3 days by neutral red dye method Antiviral activity against Herpes simplex virus type 1 infected in Vero cells at 0.01 ID50/cells assessed as protection against virus-induced cytopathic effect after 3 days by neutral red dye method	[PMID: 23141915]
Vero	IC₅₀	0.2 μg/mL Compound: Acyclovir	Antiviral activity against HSV1 F ATCC VR733 infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days Antiviral activity against HSV1 F ATCC VR733 infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days	[PMID: 23194476]
Vero	CC₅₀	>50 μM Compound: ACV	Cytotoxicity against african green monkey Vero cells by MTT assay Cytotoxicity against african green monkey Vero cells by MTT assay	[PMID: 23419738]
Vero	EC₅₀	1.7 μM Compound: ACV	Antiviral activity against Herpes simplex virus 1 F infected in Vero cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against Herpes simplex virus 1 F infected in Vero cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	[PMID: 23419738]
Vero	EC₅₀	58.6 μM Compound: ACV	Antiviral activity against Herpes simplex virus 2 MS infected in Vero cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against Herpes simplex virus 2 MS infected in Vero cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	[PMID: 23419738]
Vero	EC₅₀	>100 μM Compound: ACG	Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	>100 μM Compound: ACG	Antiviral activity against Poliovirus type 1 Sabin strain infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay Antiviral activity against Poliovirus type 1 Sabin strain infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	>100 μM Compound: ACG	Antiviral activity against Respiratory syncytial virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 5 days by plaque reduction assay Antiviral activity against Respiratory syncytial virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 5 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	>100 μM Compound: ACG	Antiviral activity against Vaccinia Virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay Antiviral activity against Vaccinia Virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	>100 μM Compound: ACG	Antiviral activity against Vesicular stomatitis virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay Antiviral activity against Vesicular stomatitis virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	1.2 μM Compound: ACG	Antiviral activity against HSV1 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay Antiviral activity against HSV1 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	2.8 μM Compound: ACG	Antiviral activity against HSV1 infected in African green monkey Vero 76 cells after 3 days by plaque reduction assay Antiviral activity against HSV1 infected in African green monkey Vero 76 cells after 3 days by plaque reduction assay	[PMID: 25913116]
Vero	CC₅₀	>1000 μM Compound: Acyclovir	Cytotoxicity against mock-infected African green monkey Vero cells assessed as inhibition of cell survival after 3 days by CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay Cytotoxicity against mock-infected African green monkey Vero cells assessed as inhibition of cell survival after 3 days by CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay	[PMID: 26048809]
Vero	EC₅₀	>1000 μM Compound: Acyclovir	Antiviral activity against MERS-CoV EMC/2012 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay Antiviral activity against MERS-CoV EMC/2012 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay	[PMID: 26048809]
Vero	EC₅₀	3 μM Compound: Acycloguanosine	Antiviral activity against Human herpesvirus 1 KOS ATCC VR-1493 infected in African green monkey Vero 76 cells assessed as reduction of virus-plaque formation after 3 days by crystal violet staining Antiviral activity against Human herpesvirus 1 KOS ATCC VR-1493 infected in African green monkey Vero 76 cells assessed as reduction of virus-plaque formation after 3 days by crystal violet staining	[PMID: 26119992]
Vero	EC₅₀	0.66 μM Compound: 1a	Antiviral activity against Herpes simplex virus 1 strain F VR-733 infected in African green monkey Vero cells after 3 days by MTT assay Antiviral activity against Herpes simplex virus 1 strain F VR-733 infected in African green monkey Vero cells after 3 days by MTT assay	[PMID: 26460883]
Vero	EC₅₀	1.02 μM Compound: 1a	Antiviral activity against Herpes simplex virus 2 strain MS VR-540 infected in African green monkey Vero cells after 3 days by MTT assay Antiviral activity against Herpes simplex virus 2 strain MS VR-540 infected in African green monkey Vero cells after 3 days by MTT assay	[PMID: 26460883]
Vero	EC₅₀	18.9 μM Compound: 1a	Antiviral activity against Human cytomegalovirus Davis VR-807 infected in African green monkey Vero cells after 3 days by MTT assay Antiviral activity against Human cytomegalovirus Davis VR-807 infected in African green monkey Vero cells after 3 days by MTT assay	[PMID: 26460883]
Vero	EC₅₀	6.4 μM Compound: 1a	Antiviral activity against Varicella-zoster virus Ellen VR-1367 infected in African green monkey Vero cells after 3 days by MTT assay Antiviral activity against Varicella-zoster virus Ellen VR-1367 infected in African green monkey Vero cells after 3 days by MTT assay	[PMID: 26460883]
Vero	EC₅₀	0.27 μM Compound: ACV	Antiviral activity against HHV-2 VR-734-G infected in African green monkey Vero cells assessed as reduction in plaque formation administered post viral infection after 72 hrs by crystal violet staining technique Antiviral activity against HHV-2 VR-734-G infected in African green monkey Vero cells assessed as reduction in plaque formation administered post viral infection after 72 hrs by crystal violet staining technique	[PMID: 26638041]
Vero	EC₅₀	2.2 μM Compound: ACV	Antiviral activity against HHV-1 CDC Atlanta infected in African green monkey Vero cells assessed as reduction in plaque formation administered post viral infection after 72 hrs by crystal violet staining technique Antiviral activity against HHV-1 CDC Atlanta infected in African green monkey Vero cells assessed as reduction in plaque formation administered post viral infection after 72 hrs by crystal violet staining technique	[PMID: 26638041]
Vero	IC₅₀	>1700 μM Compound: ACV	Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation after 72 hrs Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation after 72 hrs	[PMID: 26638041]
Vero	EC₅₀	0.07 μM Compound: ACV	Antiviral activity against HSV1 KOS ATCC VR1493 infected in African green monkey Vero cells assessed as reduction in EGFP-positive cells treated at 2 hrs post infection measured 24 hrs post infection by flow cytometric analysis Antiviral activity against HSV1 KOS ATCC VR1493 infected in African green monkey Vero cells assessed as reduction in EGFP-positive cells treated at 2 hrs post infection measured 24 hrs post infection by flow cytometric analysis	[PMID: 26819664]
Vero	IC₅₀	0.41 μM Compound: Acyclovir	Antiviral activity against Herpes simplex virus-1 F VR 733 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Herpes simplex virus-1 F VR 733 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 27792321]
Vero	EC₅₀	3 μM Compound: Acyclovir	Antiviral activity against HSV-1 infected in African green monkey Vero cells by plaque reduction assay Antiviral activity against HSV-1 infected in African green monkey Vero cells by plaque reduction assay	[PMID: 28129981]
Vero	CC₅₀	>1000 μM Compound: Acyclovir	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay	[PMID: 28129981]
Vero	IC₅₀	3.11 x 10^-6 μM Compound: Acyclovir	Antiviral activity against HSV-2 infected in African green monkey Vero cells assessed as inhibition of virus plaque formation after 72 hrs by Giemsa staining based assay Antiviral activity against HSV-2 infected in African green monkey Vero cells assessed as inhibition of virus plaque formation after 72 hrs by Giemsa staining based assay	[PMID: 28771358]
Vero	CC₅₀	>200 μM Compound: ACV	Cytotoxicity against African green monkey Vero cells assessed as decrease in cell viability after 24 hrs by CellTiter-Glo luminescent assay Cytotoxicity against African green monkey Vero cells assessed as decrease in cell viability after 24 hrs by CellTiter-Glo luminescent assay	[PMID: 29099182]
Vero	IC₅₀	0.1 μM Compound: 1	The concentration required to inhibit the growth of viral plaques by 50% of control in plaque reduction assay The concentration required to inhibit the growth of viral plaques by 50% of control in plaque reduction assay	[PMID: 2991522]
Vero	IC₅₀	2.5 μM Compound: Acyclovir	Compound was tested for antiviral activity against Herpes Simplex virus Type-2(MS) in vero cells Compound was tested for antiviral activity against Herpes Simplex virus Type-2(MS) in vero cells	[PMID: 3040998]
Vero	IC₅₀	3.8 μM Compound: Acyclovir	Compound was tested for antiviral activity against Herpes Simplex virus Type-1(HFEM) in vero cells Compound was tested for antiviral activity against Herpes Simplex virus Type-1(HFEM) in vero cells	[PMID: 3040998]
Vero	IC₅₀	1.38 μM Compound: ACV	Antiviral activity against acyclovir-sensitive Herpes simplex virus 1 KOS infected in African green monkey Vero cells assessed as inhibition of viral replication after 48 hrs by naphthol blue-black staining-based plaque reduction assay Antiviral activity against acyclovir-sensitive Herpes simplex virus 1 KOS infected in African green monkey Vero cells assessed as inhibition of viral replication after 48 hrs by naphthol blue-black staining-based plaque reduction assay	[PMID: 30798081]
Vero	IC₅₀	3.23 μM Compound: ACV	Antiviral activity against Herpes simplex virus 2-333 infected in African green monkey Vero cells assessed as inhibition of viral replication after 48 hrs by naphthol blue-black staining-based plaque reduction assay Antiviral activity against Herpes simplex virus 2-333 infected in African green monkey Vero cells assessed as inhibition of viral replication after 48 hrs by naphthol blue-black staining-based plaque reduction assay	[PMID: 30798081]
Vero	CC₅₀	>2000 μM Compound: ACV	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by SRB assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 30798081]
Vero	IC₅₀	31 μM Compound: Acyclovir	Antiviral activity against Herpes simplex virus 2 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenic effect after 24 hrs by crystal violet staining based assay Antiviral activity against Herpes simplex virus 2 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenic effect after 24 hrs by crystal violet staining based assay	[PMID: 31975590]
Vero	CC₅₀	1100 mg/mL Compound: ACV	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32089391]
Vero	EC₅₀	1.2 mg/mL Compound: ACV	Antiviral activity against Herpes simplex virus 1 infected in African green monkey vero cells assessed as reduction in plaque formation treated 1 hr post viral infection by plaque reduction assay Antiviral activity against Herpes simplex virus 1 infected in African green monkey vero cells assessed as reduction in plaque formation treated 1 hr post viral infection by plaque reduction assay	[PMID: 32089391]
Vero	EC₅₀	12.8 mg/mL Compound: ACV	Antiviral activity against Herpes simplex virus 1 infected in African green monkey Vero cells assessed as reduction in plaque formation pretreated with compound for 1 hr followed by viral infection at 0.01 PFU/cells for 1 hr by plaque reduction assay Antiviral activity against Herpes simplex virus 1 infected in African green monkey Vero cells assessed as reduction in plaque formation pretreated with compound for 1 hr followed by viral infection at 0.01 PFU/cells for 1 hr by plaque reduction assay	[PMID: 32089391]
Vero	CC₅₀	>100 μM Compound: Acyclovir	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 3 days by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 34766503]
Vero	CC₅₀	>100 μM Compound: ACV	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 24 hrs by MTS assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 24 hrs by MTS assay	[PMID: 35635945]
Vero	ED₅₀	0.5 μM Compound: Acyclovir	Antiviral activity against HSV-1 (Herpes simplex virus) in vero cells Antiviral activity against HSV-1 (Herpes simplex virus) in vero cells	[PMID: 8289203]
Vero	ED₅₀	0.5 μM Compound: Acyclovir	Antiviral activity against HSV-2 (Herpes simplex virus) in vero cells Antiviral activity against HSV-2 (Herpes simplex virus) in vero cells	[PMID: 8289203]
Vero	IC₅₀	1.7 μM Compound: Acyclovir	Inhibitory activity against herpes simplex virus type 2 (HSV 2) strain 186 in Vero cells. Inhibitory activity against herpes simplex virus type 2 (HSV 2) strain 186 in Vero cells.	[PMID: 8576922]
Vero	IC₅₀	1.8 μM Compound: Acyclovir	Inhibitory activity against herpes simplex virus type 1 (HSV-1) strain SC16 in Vero cells. Inhibitory activity against herpes simplex virus type 1 (HSV-1) strain SC16 in Vero cells.	[PMID: 8576922]
Vero	EC₅₀	1.5 μg/mL Compound: Acyclovir	Antiviral activity against HSV2 MS in african green monkey Vero cells by viral cytopathic effect assay Antiviral activity against HSV2 MS in african green monkey Vero cells by viral cytopathic effect assay	[PMID: 9214738]
Vero	IC₅₀	>100 μg/mL Compound: Acyclovir	Cytotoxicity against african green monkey Vero cells by MTT assay Cytotoxicity against african green monkey Vero cells by MTT assay	[PMID: 9214738]
Vero	CC₅₀	820 μg/mL Compound: 1a(ACV)	Cytotoxic concentration to uninfected vero cells Cytotoxic concentration to uninfected vero cells	[PMID: 9548818]
Vero	IC₅₀	0.81 μg/mL Compound: 1a(ACV)	Inhibition of Tomioka strain of herpes simplex virus( Tomioka strain of HSV-1) by quantitative CPE reduction assay in vero cells Inhibition of Tomioka strain of herpes simplex virus( Tomioka strain of HSV-1) by quantitative CPE reduction assay in vero cells	[PMID: 9548818]
Vero	IC₅₀	>44.4 μM Compound: Acyclovir	Comparative Potency (IC50s) at HSV-2 passage 2 in vero cells Comparative Potency (IC50s) at HSV-2 passage 2 in vero cells	[PMID: 9685239]
Vero	IC₅₀	>88.8 μM Compound: Acyclovir	Comparative Potency (IC50s) at HSV-1 passage 3 in vero cells Comparative Potency (IC50s) at HSV-1 passage 3 in vero cells	[PMID: 9685239]
Vero	IC₅₀	>88.8 μM Compound: Acyclovir	Comparative Potency (IC50s) at HSV-2 passage 4 in vero cells Comparative Potency (IC50s) at HSV-2 passage 4 in vero cells	[PMID: 9685239]
Vero	IC₅₀	111 μM Compound: Acyclovir	Comparative Potency (IC50s) at HSV-1 passage 5 in vero cells Comparative Potency (IC50s) at HSV-1 passage 5 in vero cells	[PMID: 9685239]
Vero	IC₅₀	130.7 μM Compound: Acyclovir	Comparative Potency (IC50s) at HSV-1 passage 6 in vero cells Comparative Potency (IC50s) at HSV-1 passage 6 in vero cells	[PMID: 9685239]
Vero	IC₅₀	138.4 μM Compound: Acyclovir	Comparative Potency (IC50s) at HSV-1 passage 4 in vero cells Comparative Potency (IC50s) at HSV-1 passage 4 in vero cells	[PMID: 9685239]
Vero	IC₅₀	189.8 μM Compound: Acyclovir	Comparative Potency (IC50s) at HSV-1 passage 7 in vero cells Comparative Potency (IC50s) at HSV-1 passage 7 in vero cells	[PMID: 9685239]
Vero	IC₅₀	37.8 μM Compound: Acyclovir	Comparative Potency (IC50s) at HSV-1 passage 2 in vero cells Comparative Potency (IC50s) at HSV-1 passage 2 in vero cells	[PMID: 9685239]
Vero	IC₅₀	378.8 μM Compound: Acyclovir	Comparative Potency (IC50s) at HSV-1 passage 9 in vero cells Comparative Potency (IC50s) at HSV-1 passage 9 in vero cells	[PMID: 9685239]
Vero	IC₅₀	444 μM Compound: Acyclovir	Comparative Potency (IC50s) at HSV-1 passage 8 in vero cells Comparative Potency (IC50s) at HSV-1 passage 8 in vero cells	[PMID: 9685239]
Vero	IC₅₀	6.66 μM Compound: Acyclovir	Comparative Potency (IC50s) at HSV-2 passage 1 in vero cells Comparative Potency (IC50s) at HSV-2 passage 1 in vero cells	[PMID: 9685239]
Vero	IC₅₀	62.8 μM Compound: Acyclovir	Comparative Potency (IC50s) at HSV-2 passage 3 in vero cells Comparative Potency (IC50s) at HSV-2 passage 3 in vero cells	[PMID: 9685239]
Vero	CC₅₀	960 μM Compound: ACV	Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells after 72 hr by MTT assay Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells after 72 hr by MTT assay	10.1007/s00044-007-9035-6
Vero	EC₅₀	1.09 μM Compound: ACV	Antiviral activity against Human herpesvirus 1 infected in Vero cells after 72 hr by plaque reduction assay Antiviral activity against Human herpesvirus 1 infected in Vero cells after 72 hr by plaque reduction assay	10.1007/s00044-007-9035-6
Vero	CC₅₀	1275 μg/mL Compound: Acyclovir	Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells assessed as cell viability after 3 days by Alamar blue assay Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells assessed as cell viability after 3 days by Alamar blue assay	10.1007/s00044-011-9574-8
Vero	EC₅₀	1.5 μg/mL Compound: Acyclovir	Antiviral activity against Human herpesvirus 1 infected African green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 3 days by plaque reduction assay Antiviral activity against Human herpesvirus 1 infected African green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 3 days by plaque reduction assay	10.1007/s00044-011-9574-8
Vero	EC₅₀	3 μM Compound: ACG	Antiviral activity against Human herpesvirus 1 infected African green monkey Vero 76 cells assessed as reduction in plaque number treated after viral infection measured after 3 days by plaque reduction assay Antiviral activity against Human herpesvirus 1 infected African green monkey Vero 76 cells assessed as reduction in plaque number treated after viral infection measured after 3 days by plaque reduction assay	10.1007/s00044-012-0342-1
Vero	CC₅₀	>100 μM Compound: Acyclovir	The lowest concentration of compound producing overt cytotoxicity in virus-free vero cell cultures The lowest concentration of compound producing overt cytotoxicity in virus-free vero cell cultures	10.1016/0960-894X(95)00208-B
Vero	EC₅₀	3 μM Compound: Acyclovir	Anti-herpes virus activity was evaluated against Herpes simplex virus type 2 (HSV-2,strain G) grown in Vero cells Anti-herpes virus activity was evaluated against Herpes simplex virus type 2 (HSV-2,strain G) grown in Vero cells	10.1016/0960-894X(95)00208-B
Vero	EC₅₀	6 μM Compound: Acyclovir	Anti-herpes virus activity was evaluated against Herpes simplex virus type 1 (HSV-1,strain HF) grown in Vero cells Anti-herpes virus activity was evaluated against Herpes simplex virus type 1 (HSV-1,strain HF) grown in Vero cells	10.1016/0960-894X(95)00208-B
Vero	EC₅₀	0.32 μg/mL Compound: Acyclovir	In vitro evaluation of antiviral activity against HSV-1 (Herpes simplex virus-1) induced cytopathic effect in vero cells by a plaque reduction assay In vitro evaluation of antiviral activity against HSV-1 (Herpes simplex virus-1) induced cytopathic effect in vero cells by a plaque reduction assay	10.1016/0960-894X(95)00395-A
Vero	EC₅₀	0.39 μg/mL Compound: Acyclovir	In vitro evaluation of antiviral activity against HSV-2 (Herpes simplex virus-2) induced cytopathic effect in vero cells by a plaque reduction assay In vitro evaluation of antiviral activity against HSV-2 (Herpes simplex virus-2) induced cytopathic effect in vero cells by a plaque reduction assay	10.1016/0960-894X(95)00395-A
Vero	IC₅₀	1.5 μg/mL Compound: Acyclovir	Concentration required for 50% inhibition of herpes simplex virus 2(HSV-2) using standard plaque reduction assay in vero cells Concentration required for 50% inhibition of herpes simplex virus 2(HSV-2) using standard plaque reduction assay in vero cells	10.1016/S0960-894X(01)80236-5
Vero	CC₅₀	>10 μg/mL Compound: ACV	Cytotoxicity in Vero cell line Cytotoxicity in Vero cell line	10.1016/S0960-894X(01)80693-4
Vero	IC₅₀	0.1 μg/mL Compound: ACV	Inhibitory activity against Herpes Simplex virus type 1 (KOS strain) in a Plaque reduction Assay in vero cells Inhibitory activity against Herpes Simplex virus type 1 (KOS strain) in a Plaque reduction Assay in vero cells	10.1016/S0960-894X(01)80693-4
Vero	IC₅₀	0.5 μg/mL Compound: ACV	Inhibitory activity against Herpes Simplex virus type 1 (186 strain) in a Plaque reduction Assay in vero cells Inhibitory activity against Herpes Simplex virus type 1 (186 strain) in a Plaque reduction Assay in vero cells	10.1016/S0960-894X(01)80693-4
Vero	IC₅₀	50 μg/mL Compound: Acyclovir	In vitro inhibitory concentration for antiviral activity was tested against vero cells In vitro inhibitory concentration for antiviral activity was tested against vero cells	10.1016/S0960-894X(97)00365-X
Vero 76	EC₅₀	>100 μM Compound: ACG	Antiviral activity against Coxsackie virus type B2 virus infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay Antiviral activity against Coxsackie virus type B2 virus infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay	[PMID: 19482481]
Vero 76	EC₅₀	>100 μM Compound: ACG	Antiviral activity against Respiratory syncytial virus A2 infected in Vero-76 cells after 5 days by plaque reduction assay Antiviral activity against Respiratory syncytial virus A2 infected in Vero-76 cells after 5 days by plaque reduction assay	[PMID: 19482481]
Vero 76	EC₅₀	3 μM Compound: ACG	Antiviral activity against HSV1 infected in Vero-76 cells after 3 days by plaque reduction assay Antiviral activity against HSV1 infected in Vero-76 cells after 3 days by plaque reduction assay	[PMID: 19482481]
Vero 76	EC₅₀	3 μM Compound: Acycloguanosine	Antiviral activity against Herpes simplex virus type 1 KOS ATCC VR-1493 infected in african green monkey Vero-76 cells assessed as reduction in viral plaque after 3 days by crystal violet staining Antiviral activity against Herpes simplex virus type 1 KOS ATCC VR-1493 infected in african green monkey Vero-76 cells assessed as reduction in viral plaque after 3 days by crystal violet staining	[PMID: 22513121]
Vero 76	CC₅₀	>100 μM Compound: ACG	Cytotoxicity against mock-infected African green monkey Vero 76 cells assessed as reduction in proliferation after 48 to 96 hrs by MTT method Cytotoxicity against mock-infected African green monkey Vero 76 cells assessed as reduction in proliferation after 48 to 96 hrs by MTT method	[PMID: 25014745]
Vero 76	EC₅₀	3 μM Compound: ACG	Antiviral activity against Human herpesvirus 1 strain KOS ATCC VR- 1493 infected in Vero 76 cells after 3 days by plaque reduction assays Antiviral activity against Human herpesvirus 1 strain KOS ATCC VR- 1493 infected in Vero 76 cells after 3 days by plaque reduction assays	[PMID: 25014745]
Vero 76	CC₅₀	>100 μM Compound: ACG	Cytotoxicity against mock-infected african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay Cytotoxicity against mock-infected african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay	[PMID: 25082514]
Vero 76	CC₅₀	>100 μM Compound: ACG	Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by MTT method Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by MTT method	[PMID: 25913116]
Vero 76	CC₅₀	13 μM Compound: Acycloguanosine	Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining	[PMID: 26119992]
Vero 76	CC₅₀	>100 μM Compound: ACG	Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining method Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining method	[PMID: 26443549]
Vero 76	EC₅₀	>100 μM Compound: ACG	Antiviral activity against human CVB5 infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 3 days by plaque reduction assay Antiviral activity against human CVB5 infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 3 days by plaque reduction assay	[PMID: 26443549]
Vero 76	EC₅₀	>100 μM Compound: ACG	Antiviral activity against Human poliovirus 1 Sabin infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity by plaque reduction assay Antiviral activity against Human poliovirus 1 Sabin infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity by plaque reduction assay	[PMID: 26443549]
Vero 76	EC₅₀	>100 μM Compound: ACG	Antiviral activity against human RSV infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by plaque reduction assay Antiviral activity against human RSV infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by plaque reduction assay	[PMID: 26443549]
Vero 76	EC₅₀	>100 μM Compound: ACG	Antiviral activity against CVB-5 virus Faulkner ATCC VR-185 infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay Antiviral activity against CVB-5 virus Faulkner ATCC VR-185 infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay	[PMID: 26479028]
Vero 76	EC₅₀	3 μM Compound: ACG	Antiviral activity against HSV-1 KOS ATCC VR- 1493 infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay Antiviral activity against HSV-1 KOS ATCC VR- 1493 infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay	[PMID: 26479028]
Vero 76	CC₅₀	>100 μM Compound: ACG	Cytotoxicity against mock-infected african green monkey Vero 76 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay Cytotoxicity against mock-infected african green monkey Vero 76 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay	[PMID: 27161176]
Vero 76	EC₅₀	1.5 μM Compound: ACG	Antiviral activity against Vaccinia virus Elstree infected in Vero 76 cells after 3 days by crystal violet staining based plaque reduction assay Antiviral activity against Vaccinia virus Elstree infected in Vero 76 cells after 3 days by crystal violet staining based plaque reduction assay	[PMID: 27161176]
Vero 76	CC₅₀	>100 μM Compound: ACG	Cytotoxicity against African green monkey Vero 76 cells assessed as decrease in cell viability after 48 to 96 hrs by MTT assay Cytotoxicity against African green monkey Vero 76 cells assessed as decrease in cell viability after 48 to 96 hrs by MTT assay	[PMID: 29028528]
Vero 76	EC₅₀	3 μM Compound: ACG	Antiviral activity against Human herpesvirus 1 infected African green monkey Vero76 cells assessed as reduction of virus-induced plaque reduction after 3 days by MTT assay Antiviral activity against Human herpesvirus 1 infected African green monkey Vero76 cells assessed as reduction of virus-induced plaque reduction after 3 days by MTT assay	10.1007/s00044-010-9513-0
Vero C1008	CC₅₀	>1000 μM Compound: Acyclovir	Cytotoxicity against mock-infected African green monkey Vero E6 cells assessed as inhibition of cell survival after 3 days by CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay Cytotoxicity against mock-infected African green monkey Vero E6 cells assessed as inhibition of cell survival after 3 days by CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay	[PMID: 26048809]
Vero C1008	IC₅₀	>444 μM Compound: ACV	Antiviral activity against acyclovir and foscarnet-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against acyclovir and foscarnet-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect	[PMID: 28408228]
Vero C1008	IC₅₀	>444 μM Compound: ACV	Antiviral activity against acyclovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against acyclovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect	[PMID: 28408228]
Vero C1008	IC₅₀	1.73 μM Compound: ACV	Antiviral activity against HSV1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against HSV1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect	[PMID: 28408228]
Vero C1008	IC₅₀	17.3 μM Compound: ACV	Antiviral activity against acyclovir and cidofovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against acyclovir and cidofovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect	[PMID: 28408228]
Vero C1008	IC₅₀	27.8 μM Compound: ACV	Antiviral activity against HSV-1 L2/Rp-ACV/2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against HSV-1 L2/Rp-ACV/2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect	[PMID: 28408228]
Vero C1008	IC₅₀	3.5 μM Compound: ACV	Antiviral activity against foscarnet-resistant HSV-1 F+ infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against foscarnet-resistant HSV-1 F+ infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect	[PMID: 28408228]
WISH	ED₅₀	1411 μM Compound: Acyclovir	Antiviral activity against vesicular stomatitis virus infected in human WISH cells Antiviral activity against vesicular stomatitis virus infected in human WISH cells	[PMID: 25515560]

In Vitro

Acyclovir (Aciclovir, 3-100 μM; 24-72 hours; Jurkat, U937, and K562 leukemia cells) reduces cell viability in a dose- and time-dependent^[1].
Acyclovir (Aciclovir, 10-100 μM; 24-72 hours; Jurkat cells) blocks DNA synthesis, thereby arresting the cell cycle in G2/M and S phases and increasing the sub-G1 hypodiploid peak in a dose-dependent manner^[1].
Acyclovir (Aciclovir, 10-100 μM; 24-72 hours; Jurkat cells) induces apoptosis through activates caspase-3 and presences nuclear DNA fragmentation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

Jurkat, U937 and K562 leukemia cells
Concentration:

3, 10, 30 and 100 µM
Incubation Time:

24, 48 and 72 hours
Result:

Showed a dose- and time-dependent reduction of cell viability.

Apoptosis Analysis^[3]

Cell Line:

Jurkat cells
Concentration:

10 and 100 µM
Incubation Time:

24, 48 and 72 hours
Result:

Increased of caspase-3 activity and cleavaged the internucleosomal DNA.

Cell Cycle Analysis^[1]

Cell Line:

Jurkat cells
Concentration:

10 and 100 µM
Incubation Time:

24, 48 and 72 hours
Result:

Revealed a dose-dependent accumulation of cells in S phase after 24 and 48 h. Showed a dose-dependent increase of the sub-G1 hypodiploid peak after 72 h.

In Vivo

Acyclovir (20 mg/kg; p.o.; three times daily; for 10 days; BALB/c mice) treatment in infected mice suppresses the development of skin lesions and results in a dissociation between DTH response and antibody production^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Specific-pathogen-free BALB/c mice (7-week-old) infected with HSV-1^[1]
Dosage:

20 mg/kg
Administration:

Oral administration; three times daily; for 10 days
Result:

Suppressed the development of skin lesions and resulted in a dissociation between DTH response and antibody production.

Chemical Information

CAS. Nr. 59277-89-3
Appearance Solid
Molecular Weight 225.21
Formel C₈H₁₁N₅O₃
Color White to off-white
SMILES

O=C1NC(N)=NC2=C1N=CN2COCCO
Synonyms

Aciclovir; Acycloguanosine
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (22)

All Cell Imaging/StainingCell Proliferation/Viability AssayBio/Physico-chemical AssayWB

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]

2025 Dec 15;10(1):406. PMID: 41392286
Mol Cell

Asparagine sensing by TBK1 controls its phase separation to drive antiviral innate immune responses. [Abstract]

2026 Feb 19;86(4):722-739.e8. PMID: 41653919
Sci Adv

Transition of pseudorabies virus from latency to reactivation state selectively triggered by pathogenic bacteria. [Abstract]

2025 Nov 21;11(47):eadw4206. PMID: 41259522

Acyclovir purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Nov 21;11(47):eadw4206. [Abstract]

Fluorescence microscopy images depicting N2a cells infected with different doses of HuBXY/2018-mCherry with or without Acyclovir (ACV: 200 μM) and IFN-α treatments. The images were acquired on 8 dpi.
Acta Pharmacol Sin

A small molecule compound targeting hemagglutinin inhibits influenza A virus and exhibits broad-spectrum antiviral activity. [Abstract]

2024 Nov;45(11):2380-2393. PMID: 38987389

Acyclovir purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2024 Nov;45(11):2380-2393. [Abstract]

Acyclovir (2 μM). The inhibitory effect of J1 on HSV1 (MOI = 0.1) infection in Vero cells was analyzed by plaque assay.
Phytomedicine

Inhibition of herpes simplex virus infection by Caesappanin C targeting virus gB protein and host HSP90β. [Abstract]

2026 Feb:151:157802. PMID: 41544463

Acyclovir purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2026 Feb:151:157802. [Abstract]

The antiviral activity of Acyclovir (ACV) against HSV-1 in different cell cultures was evaluated using the CPE inhibition assay (MOI = 1).
EMBO J

A novel biosensor for the spatiotemporal analysis of STING activation during innate immune responses to dsDNA. [Abstract]

2025 Apr;44(7):2157-2182. PMID: 39984755

Acyclovir purchased from MedChemExpress. Usage Cited in: EMBO J. 2025 Apr;44(7):2157-2182. [Abstract]

HeLa SIRF biosensor cells were analyzed 24 hours after being treated with a simulated method or infected with 0.5 MOI of HSV-1 virus expressing mCherry, with or without Acyclovir (50 µM).
Phytomedicine

Salvianolic acid A inhibits pseudorabies virus infection by directly inactivating the virus particle. [Abstract]

2024 Sep 1:134:156015. PMID: 39244942
Biomed Pharmacother

A potential anti-HIV-1 compound, Q308, inhibits HSV-2 infection and replication in vitro and in vivo. [Abstract]

2023 Jun:162:114595. PMID: 36989723

Acyclovir purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2023 Jun:162:114595. [Abstract]

Acyclovir (ACV; 2.5 μM; 48 h) significantly inhibits the expression of gD in HSV-2-infected HeLa, Vero, Beas-2B and HaCaT cells.
Cell Rep

Enucleated cells with Nectin-1 overexpression capture HSV-1 and promote viral elimination for herpes simplex encephalitis therapy. [Abstract]

2026 Mar 12;45(3):117099. PMID: 41824450
Eur J Med Chem

Design and syntheses of a bimolecular STING agonist based on the covalent STING antagonist. [Abstract]

2023 Mar 15:250:115184. PMID: 36758305
Drug Des Devel Ther

Antiviral Activity of Oridonin Against Herpes Simplex Virus Type 1. [Abstract]

2022 Dec 20:16:4311-4323. PMID: 36573068
Microchem J

2021, 106587.
J Med Virol

Small molecule RAF265 as an antiviral therapy acts against HSV-1 by regulating cytoskeleton rearrangement and cellular translation machinery. [Abstract]

2023 Jan;95(1):e28226. PMID: 36251738
Front Microbiol

In vitro Studies and Clinical Observations Imply a Synergistic Effect Between Epstein-Barr Virus and Dengue Virus Infection. [Abstract]

2021 Jun 18:12:691008. PMID: 34220783
Antiviral Res

Flexible nano-liposomes-encapsulated recombinant UL8-siRNA (r/si-UL8) based on bioengineering strategy inhibits herpes simplex virus-1 infection. [Abstract]

2024 Jun 21:228:105936. PMID: 38908520
Antiviral Res

Pralatrexate inhibited the replication of varicella zoster virus and vesicular stomatitis virus: An old dog with new tricks. [Abstract]

2024 Jan:221:105787. PMID: 38145756
Virol J

Small molecule UCM05 inhibits HSV-2 infection via targeting viral glycoproteins and fatty acid synthase with potentiating antiviral immunity. [Abstract]

2025 Jul 19;22(1):249. PMID: 40684179
Microb Pathog

mTORC2-dependent autophagy inhibition regulates the replication of HSV-1 and adenovirus in viral keratitis & conjunctivitis. [Abstract]

2026 Apr:213:108349. PMID: 41628839
Mol Med Rep

Identification of metabolites associated with capecitabine‑induced hand‑foot syndrome using untargeted metabolomics in patients with cancer. [Abstract]

2025 Jul;32(1):203. PMID: 40377002
Front Oncol

Gut virome dysbiosis impairs antitumor immunity and reduces 5-fluorouracil treatment efficacy for colorectal cancer. [Abstract]

2024 Dec 19:14:1501981. PMID: 39791120
bioRxiv

2026 May 4.
University of Auckland

2025.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 50 mg/mL (222.02 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.4403 mL

22.2017 mL

44.4034 mL

5 mM

0.8881 mL

4.4403 mL

8.8807 mL

10 mM

0.4440 mL

2.2202 mL

4.4403 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (11.10 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (11.10 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 20 mg/mL (88.81 mM); Suspended solution; Need ultrasonic

Protocol 2

Add each solvent one by one: 0.5% CMC/saline water

Solubility: 20 mg/mL (88.81 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Benedetti S, et, al. Acyclovir induces cell cycle perturbation and apoptosis in Jurkat leukemia cells, and enhances chemotherapeutic drug cytotoxicity. Life Sci. 2018 Dec 15;215:80-85. [Content Brief]

[2]. Suzuki M, et, al. Synergistic antiviral activity of acyclovir and vidarabine against herpes simplex virus types 1 and 2 and varicella-zoster virus. Antiviral Res. 2006 Nov;72(2):157-61. [Content Brief]

[3]. Li Z, et, al. Acyclovir treatment of skin lesions results in immune deviation in mice infected cutaneously with herpes simplex virus. Antivir Chem Chemother. 1999 Sep;10(5):251-7. [Content Brief]

[4]. Lönnqvist B, et, al. Oral acyclovir as prophylaxis for bacterial infections during induction therapy for acute leukaemia in adults. The Leukemia Group of Middle Sweden. Support Care Cancer. 1993 May;1(3):139-44. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.4403 mL	22.2017 mL	44.4034 mL	111.0085 mL
	5 mM	0.8881 mL	4.4403 mL	8.8807 mL	22.2017 mL
	10 mM	0.4440 mL	2.2202 mL	4.4403 mL	11.1008 mL
	15 mM	0.2960 mL	1.4801 mL	2.9602 mL	7.4006 mL
	20 mM	0.2220 mL	1.1101 mL	2.2202 mL	5.5504 mL
	25 mM	0.1776 mL	0.8881 mL	1.7761 mL	4.4403 mL
	30 mM	0.1480 mL	0.7401 mL	1.4801 mL	3.7003 mL
	40 mM	0.1110 mL	0.5550 mL	1.1101 mL	2.7752 mL
	50 mM	0.0888 mL	0.4440 mL	0.8881 mL	2.2202 mL
	60 mM	0.0740 mL	0.3700 mL	0.7401 mL	1.8501 mL
	80 mM	0.0555 mL	0.2775 mL	0.5550 mL	1.3876 mL
	100 mM	0.0444 mL	0.2220 mL	0.4440 mL	1.1101 mL

Keywords

Acyclovir

22 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Acyclovir

Anti-Infection Compound Library

Apoptosis Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

CNS-Penetrant Compound Library

Drug Repurposing Compound Library

Antibacterial Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Blood Cancer Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Off-patent Drug Library

Cell Death Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Nephrotoxicity Compound Library

Drug Fragment Library

Publications Citing Use of MedChemExpress (MCE) Acyclovir

Alle HSV Isoform-spezifische Produkte anzeigen

Alle Antibiotic Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (22)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Acyclovir Related Classifications

Art. -Nr.: HY-17422